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a  b  s  t  r  a  c  t
N-acetylcysteine  (NAC)  is  recognized  for its  role  in acetaminophen  overdose  and  as  a mucolytic.  Over
the  past  decade,  there  has  been  growing  evidence  for the use of NAC  in  treating  psychiatric  and  neu-
rological  disorders,  considering  its  role  in  attenuating  pathophysiological  processes  associated  with
these  disorders,  including  oxidative  stress,  apoptosis,  mitochondrial  dysfunction,  neuroinﬂammationvailable online 6 May  2015
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and  glutamate  and  dopamine  dysregulation.  In this  systematic  review  we ﬁnd  favorable  evidence  for  the
use of NAC  in several  psychiatric  and  neurological  disorders,  particularly  autism,  Alzheimer’s  disease,
cocaine  and  cannabis  addiction,  bipolar  disorder,  depression,  trichotillomania,  nail  biting,  skin  picking,
obsessive-compulsive  disorder,  schizophrenia,  drug-induced  neuropathy  and  progressive  myoclonic
Abbreviations: ABC, Aberrant Behavior Checklist; AD, Alzheimer’s disease; ADCS-ADL, Alzheimer’s Disease Cooperative Study – Activities of Daily Living; ADHD, attention
eﬁcit  hyperactivity disorder; ADL, Activities of Daily Living; ADP, adenosine diphosphate; AE, adverse effects; AIMS, Abnormal Involuntary Movement Scale; ALL, acute
ymphoblastic leukemia; ALS, amyotrophic lateral sclerosis; AN, animal naming test; ASD, autism spectrum disorder; ASRS, ADHD Self Report Scale; ATP, adenosine triphos-
hate;  BAS, Barnes Akathisia Scale; BDRS, Bipolar Depression Rating Scale; BE, benzoylecgonine; BID, twice daily; BP, blood pressure; BPAD, bipolar disorder; BSCS, Brief
ubstance Craving Scale; CCQ-Brief, Cocaine Craving Questionnaire-Brief; CGI, Clinical Global Impression; CGI-I, Clinical Global Impression – Improvement; CGI-S, Clinical
lobal Impression – Severity; CLOX-1, Clock Drawing Executive Test; CO, carbon monoxide; COWA, Controlled Oral Word Association Test; CSSA, Cocaine Selective Severity
ssessment; DA, dopamine; DBPC, Double Blind Placebo Control Trial; DE, detrimental; Dep, depressive disorder; DNA, deoxyribonucleic acid; DRS-2, Dementia Rating
cale-2; DTE, dithioerythritol; DTT, dithiothreitol; ESRS, Extrapyramidal Symptom Rating Scale; F, female; FDA, Food and Drug Administration; FTQ, Fagerström Tolerance
uestionnaire; g/d, grams per day; G, grams; GAF, Global Assessment of Functioning; GI, gastrointestinal; GOR, grade of recommendation; G-SAS, Gambling Symptom Assess-
ent  Scale; GSH, glutathione; GSSG, glutathione disulphide; GTCS, Generalized Tonic Clonic Seizures; HA, headache; HARS, Hamilton Anxiety Rating Scale; HDRS, Hamilton
epression Rating Scale; HIV, human immunodeﬁciency virus; 5-HT, serotonin; ICAM, intercellular adhesion molecule; IFN, interferon; IL, interleukin; IU,  international units;
IFE-RIFT, Longitudinal Interval Follow-up Evaluation Range of Impaired Functioning Tool; LOE, level of evidence; LPS, lipopolysacchride; LTD, long term depression; LTP,
ong  term potentiation; M, male; MADRS, Montgomery–Asberg Depression Scale; MAOI, monoamine oxidase inhibitor; MAP, methamphetamine; MCQ, Marijuana Craving
uestionnaire; MDD, major depressive disorder; g, micrograms; mg,  milligrams; MGH-HPS, Massachusetts General Hospital Hair Pulling Scale; MMSE, Mini-Mental Status
xamination; MNWS,  Minnesota Nicotine Withdrawal Scale; mRNA, messenger ribonucleic acid; NA, nucleus accumbens; NAC, N-acetylcysteine; NACA, N-acetylcysteine
mide; NAM, N-acetylmethionine; NE, neutral effect; NF-B, nuclear factor kappa-light-chain-enhancer of activated B cells; NIMH-TSS, National Institute of Mental Health
richotillomania Severity Scale; NMDA, N-methyl d-aspartate; NPI, Neuropsychiatric Inventory; NR, not reported; OCD, obsessive compulsive disorder; OR, odds ratio;
ANSS, Positive and Negative Syndrome Scale; PB, placebo; PFC, pre-frontal cortex; PG, pathological gambling; PG-YBOCS, Pathological Gambling-Yale-Brown Obsessive
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richotillomania; UDS, urine drug screen; ULD, Unverricht–Lundborg Disease; VAS, Visual Analog Scale; Vit, vitamin; Wk,  weeks; Y-BOCS, Yale Brown Obsessive Compulsive
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epilepsy.  Disorders  such  as anxiety,  attention  deﬁcit  hyperactivity  disorder  and  mild  traumatic  brain
injury have  preliminary  evidence  and  require  larger  conﬁrmatory  studies  while  current  evidence does
not  support  the  use  of  NAC  in gambling,  methamphetamine  and  nicotine  addictions  and  amyotrophic
lateral  sclerosis.  Overall,  NAC  treatment  appears  to  be safe  and tolerable.  Further  well  designed,  larger
controlled  trials  are  needed  for speciﬁc  psychiatric  and  neurological  disorders  where  the  evidence  is
favorable.
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. Introduction
N-acetylcysteine (NAC) is acetyl derivative of the amino acid
ysteine (Arakawa and Ito, 2007). It is widely available as an over-
he-counter nutritional supplement with antioxidant properties
Berk et al., 2013). NAC is considered a well-tolerated and safe
edication that has been used all across the world in variety of
edical conditions for past several decades (LaRowe et al., 2006).
t is widely recognized for its role as an antidote of acetaminophen
verdose (Green et al., 2013). For acetaminophen overdose, NAC
as been FDA approved as oral 72-h protocol since 1985 in the
nited States (Yarema et al., 2009). Outside of the Unites States, the
0-h intravenous protocol has been preferable and FDA approved
nephropathy (Quintavalle et al., 2013), as a preventive agent for
atrial ﬁbrillation (Liu et al., 2014) and as adjunct therapy in HIV-
infection (De Rosa et al., 2000). Additionally it has shown to
inhibit replication of the seasonal inﬂuenza A virus and could
be a potential treatment in inﬂuenza A infection (Geiler et al.,
2010).
Over the past decade, there has been a growing interest in
using NAC to treat psychiatric and neurological disorders. Evi-
dence based on preclinical research studies suggest that NAC
may  modulate pathophysiological processes that are involved in
multiple psychiatric and neurological disorders, including oxida-
tive stress, neurogenesis and apoptosis, mitochondrial dysfunction,he intravenous form for use in acetaminophen overdose in the
nited States in 2004 (Yarema et al., 2009). It is also used as a
ucolytic in chronic obstructive pulmonary disease (Dekhuijzen
nd van Beurden, 2006), a renal protectant in contrast-inducedneuroinﬂammation and dysregulation of glutamate and dopamine
neurotransmitter systems (Dean et al., 2011; Samuni et al., 2013).
In addition, it is also believed to have a role in long-term neuroad-
aptation and metaplasticity that is very important in a number
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for each disorder. Following the discussion of the potential effec-
tiveness of NAC, a section discusses the reported adverse effects96 Deepmala et al. / Neuroscience and 
f psychiatric disorders (Moussawi et al., 2009; Reichel et al.,
011).
Over the past decade, clinical reports have documented the
utcome of treatment with NAC for a multitude of psychiatric
nd neurological disorders, including schizophrenia, bipolar disor-
er, skin picking, trichotillomania, obsessive-compulsive disorder,
utism and addiction to nicotine, cannabis, cocaine, metham-
hetamine, gambling (Berk et al., 2013); as well as epilepsy,
myotrophic lateral sclerosis, neuropathy (Bavarsad Shahripour
t al., 2014) and traumatic brain injury (Hoffer et al., 2013). Given
he growing number of studies on its use as a treatment interven-
ion in psychiatry and neurology, along with a very good safety and
olerability proﬁle, we aimed to systematically review the litera-
ure and critically evaluate the level of evidence concerning the use
f NAC for treating psychiatric and neurological disorders. Such a
ystematic evaluation has allowed us to produce a grade of recom-
endation for each psychiatric and neurological disorder. To this
nd, this manuscript can help us understand in which disorders
AC may  be clinically useful, in which disorders NAC may  not be
seful and in which disorders more studies are required to make
uch a judgment. We  particularly concentrate on the evidence for
ny adverse effects during the use of NAC in controlled clinical tri-
ls to assess whether NAC is safe for the treatment of psychiatric
nd neurological disorders.
. Method
The PICO (Problem-Intervention-Comparison-Outcomes)
ramework was used to conduct this review (Richardson et al.,
995). The goal was to identify research studies that reported NAC
s a treatment to improve all common psychiatric and neurological
isorders. We  did not compare NAC treatment to other treatment
nd we considered all clinical study designs. Our primary goal was
o consider improvement in all outcomes reported in the clinical
tudies review as well as determine the prevalence of adverse
ffects with NAC treatment.
.1. Search strategy
A systematic online literature search of PUBMED, Ovid
edline, Psych info, Google Scholar, CINAHL, EmBase, Scopus,
ochrane and ERIC databases from inception through March
015 was conducted using search terms – “N-acetylcysteine”,
acetylcysteine” or “NAC” AND broad search term – “psy-
hiatry”, “psychiatric disorder”, “mental illness”, “neurology”,
neurological disorder” or “addiction” OR speciﬁc psychiatric
nd neurological disorder – “autism”, “autistic disorder”, “ASD”,
Asperger’s”, “pervasive developmental disorder”, “depressive
isorder”, “major depression”, “bipolar disorder”, “mania”, “hypo-
ania”, “psychosis”, “schizophrenia”, “anxiety”, “attention deﬁcit
yperactivity disorder”, “ADHD”, “obsessive compulsive disorder”,
OCD”, “methylphenidate”, “amphetamine”, “methamphetamine”,
cocaine”, “cannabis”, “marijuana”, “heroin”, “prescription pills”,
opioids”, “benzodiazepine”, “nicotine”, “pathological gambling”,
trichotillomania”, “nail biting”, “skin picking”, “impulse con-
rol disorder”, “amyotrophic lateral sclerosis”, “ALS”, “epilepsy”,
seizures”, “traumatic brain injury”, “TBI”, “stroke”, “neuropathy”,
Parkinson’s disease”, “Huntington’s disease”, or “multiple scle-
osis”. The references cited in the identiﬁed publications were
earched for additional studies.
.2. Study selectionOne reviewer screened titles and abstracts of all potentially rele-
ant publications. All the abstracts were divided into ﬁve reviewers.
ll the reviewers independently went through their section toavioral Reviews 55 (2015) 294–321
select articles based on inclusion and exclusion criteria. Studies
were initially included if they met  all of the following criteria: (a)
human clinical trials that included randomized controlled trials,
non-randomized trials, case studies and/or case series, (b) studies
on psychiatric and neurological disorders, and (c) reported a direct
clinical effect of NAC as an outcome. Studies were excluded if they:
(a) did not involve humans, (b) did not present new or unique data
(review articles, letter to the editor, duplicate article), (c) did not
measure a clinical outcome related to effect of NAC, or (d) only
reported a non-clinical measure.
2.3. Level of evidence ratings
Although we considered conducting a meta-analysis on each
psychiatric and neurological disorder, the lack of standard
outcomes and the limitations in study design prevented a meta-
analysis of any identiﬁed disorder. As an alternative, we provide a
grade of recommendation (GOR) for each psychiatric and neuro-
logical disorder based on the level of evidence (LOE) for each study.
Using a well-established scale (Howick et al., 2011), each study was
individually assessed to determine the LOE, ranging from level 1 to 5
(see Table 1). After assessing all identiﬁed studies for each disorder,
a GOR ranging from A (solid evidence) to D (limited, inconsistent or
inconclusive evidence) was assigned (see Table 2) to each disorder.
Since a treatment could be a GOR of D for several reasons, we spec-
iﬁed if the treatment received this rating because the evidence was
a single case-report or series (SC), demonstrated a neutral effect
(NE) or was  found to be possibly detrimental (DE).
2.4. Data analysis and synthesis
We  summarized and synthesized the information about various
psychiatric and neurological disorders in several ways. A GOR for
each psychiatric and neurological disorder is summarized based on
the LOE for each study identiﬁed in Table 3. Since the GOR is based
on the quality of the clinical study and not necessarily the outcome,
we outline whether NAC should be recommended for the speciﬁc
psychiatric and neurological disorder based on both the strength
of the evidence and the outcome of the studies. A study was  given
1 point for positive outcomes on all primary and secondary mea-
sures and 0 for negative outcomes on all measures. The studies were
given 0.5 point if the study was  positive for few but not all outcomes
(either primary or secondary) or positive in subgroup analysis only.
Based on points, the percentage positive of total studies was calcu-
lated. If the overall percentage was less that 50%, independent of
the GOR, then the recommendation for treatment was ‘NO’ to use
NAC for that speciﬁc disorder based on current research. If 100%
of the studies were positive and GOR was either A or B, then the
recommendation for treatment was ‘YES’ to use NAC for that spe-
ciﬁc disorder. For percentage positive between 50% and 100% or
GOR was either C or D, then recommendation for treatment was
‘MIXED’. If there was only one study on a disorder, the recommen-
dation for clinical treatment was  ‘NONE’ as it is not advisable to base
treatment on one study. Number of studies was  based on actual trial
conducted and not number of articles to avoid duplication. For each
psychiatric and neurological disorder, a table provides the details
of each study along with the LOE grading and point based on out-
comes. In addition, the text discusses the summary of all the studiesbased on the reports from the controlled clinical trials. Finally the
discussion synthesizes this information to summarize the potential
clinical use of NAC in psychiatric and neurological disorders along
with its mechanism of action.
Deepmala et al. / Neuroscience and Biobehavioral Reviews 55 (2015) 294–321 297
Table  1
Levels of evidence.
Level Description
1a SR or meta-analysis of RCTs with homogeneity or Cochrane review with favorable ﬁndings
1b  Prospective high-quality RCT (medium sized with N between 50 and 100 or large sized with N over 100 and/or higher validity trials based on
adequate follow-up, intent to treat analysis, baseline similarity, equal treatment and dropout rates)
2a  SR of cohort (prospective, nonrandomized) studies with homogeneity
2b  Individual cohort (prospective, nonrandomized) study or low-quality RCT (small sized with N less than 50 and/or lower validity trials based on
adequate follow-up, intent to treat analysis, baseline similarity, equal treatment and dropout rates)
3a  SR of case–control (retrospective) studies with homogeneity
3b Individual case–control (retrospective) study
4  Open label trials, case series or reports
5  Expert opinion without critical appraisal or based on physiology or bench research
RCT, randomized controlled trial; SR, systematic review.
Table 2
Grade of recommendation.
Grade Description
A At least one level 1a study or two  level 1b studies
B  At least one level 1b, 2a, or 3a study, or two  level 2b or 3b studies
C  At least one level 2b or 3b study, or two level 4 studies
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SD  Level 5 evidence, or troublingly inconsistent or
N  No studies identiﬁed
. Results
.1. Evidence of effectiveness of NAC in the treatment of
sychiatric and neurological disorders
A total of 65 publications met  inclusion and exclusion criteria.
hese studies included several psychiatric and neurological disor-
ers, including addiction to cocaine, nicotine, methamphetamine,
annabis and gambling, Alzheimer’s disease (AD), Amyotrophic
ateral Sclerosis (ALS), anxiety disorder, attention deﬁcit hyperac-
ivity disorder (ADHD), autism, bipolar disorder (BPAD), depressive
isorder, epilepsy, impulse control disorder including trichotil-
omania, skin picking and nail biting, neuropathy, obsessive
ompulsive disorder (OCD), schizophrenia, and traumatic brain
njury (TBI). Each of these disorders is reviewed in a separate section
elow. Fig. 1A–M outlines the ﬂow diagrams of article screening and
election for each disorder (see Appendix 1).
able 3
verall ratings of NAC based on clinical studies presented by condition.
Psychiatric and
neurological condition
Uncontrolled studies
Positive%
(positive/total)
Contro
Positiv
(positiv
Addiction – cannabis 50% (0.5/1) 50% (0
Addiction – cocaine 100% (1/1) 50% (1
Addiction – methamphetamine 25% (0
Addiction – nicotine 33% (2
Addiction – pathological gambling 100% (1/1) 25% (0
Alzheimer’s disease 100% (2/2) 50% (0
Amyotrophic lateral sclerosis 50% (1/2) 0% (0
Anxiety 100% (1/1) 
Attention-deﬁcit hyperactivity disorder 100% (1
Autism 100% (2/2) 50% (1
Bipolar disorder 100% (1/1) 50% (1
Depressive disorder 100% (1/1) 50% (0
Epilepsy 75% (3/4) 
Impulse control-nail biting 100% (2/2) 50% (0
Impulse control-skin picking 100% (4/4) 
Impulse control-trichotillomania 100% (4/4) 50% (1
Neuropathy 100%(1/1) 100% (1
Obsessive compulsive disorder 100% (1/1) 50% (0
Schizophrenia 100% (1/1) 75% (1
Traumatic brain injury 100% (1
C, Single Case Report.clusive studies of any level, or studies reporting no improvements
There were four sets of publications (a total of 13 published stud-
ies) that examined the same population but with different outcome
measures. One set in schizophrenia with two  publications (Berk
et al., 2008a, 2011b); one set in BPAD with six publications (Berk
et al., 2008b; Dean et al., 2012; Magalhaes et al., 2011a, 2011b, 2012,
2013); one set in cocaine addiction with two publications (LaRowe
et al., 2006, 2007); and one set in cannabis addiction with three pub-
lications (Gray et al., 2012; McClure et al., 2014; Roten et al., 2013;).
There was one publication that reported outcomes related to two
different disorders – nicotine and pathological gambling addiction
and hence this publication is discussed in both the sections (Grant
et al., 2014).
3.1.1. Addiction
NAC has been used in several clinical trials examining various
addictions, including cannabis, cocaine, methamphetamine, nico-
tine, and pathological gambling (Table 4).
lled studies
e%
e/total)
Grade of
recommendation
Recommendation for
treatment
.5/1) B Mixed
.5/3) B Mixed
.5/2) B No
/6) B No
.5/2) B No
.5/1) C Mixed
/2) B No
D – SC None
/1) C None
.5/3) B Mixed
/2) A Mixed
.5/1) B Mixed
C Mixed
.5/1) C Mixed
C Mixed
/2) B Mixed
/1) C Mixed
.5/1) C Mixed
.5/2) B Mixed
/1) B None
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Table 4
Addiction.
Study Participants
# Group (M,  F);
age (SD)
Treatment Study design Outcome
measure
Effect of NAC AE Level/point
Controlled studies
Cannabis
Gray et al.
(2012)
NAC: 58 (39M,
19F); 18.9 (1.5)
PB: 58 (45M,
13F); 18.8 (1.5)
2.4 g/d NAC or
PB for 8 wk
DBPC parallel Urine
cannabinoid
testing
OR in favor of
NAC
Vivid dreams,
irritability,
severe
heartburn
1b/0.5
Roten et al.
(2013)
NAC: 45
(gender NR);
15–21
PB: 44 (gender
NR); 15–21
MCQ No signiﬁcant
differences
Cocaine
LaRowe et al.
(2006)
13 (6M, 7F);
37.1 (7.6)
1.2 g/d NAC or
PB, every 12 h
dosing for 4
doses
DBPC crossover CSSA, craving,
self-reported
use
Reduced CSSA,
craving and
self-reported
use
Pruritus,
headache,
ﬂatu-
lence/diarrhea,
abdominal
cramps, local
rash, fatigue,
elevated BP,
sweating, chest
pain, dizziness
2b/0.5
LaRowe et al.
(2007)
15 (7M, 8F);
37.4 (7.1)
Physiologic
response to
cue,
motivational
measures
Reduced
viewing time,
desire and
interest. No
change in
physiologic
response and
craving
Amen et al.
(2011)
6 (4M, 2F); 41.8
(7.4)
2.4 g/d NAC or
Baclofen for 16
days
Single blind
cross over
VAS ratings of
rush, high,
craving
NAC reduced
cravings.
No effect on
rush, high
NR 2b/0.5
LaRowe et al.
(2013)
2.4 g NAC: 33
(25M, 8F); 43
(9)
1.2 g NAC: 40
(30M, 10F); 44
(10)
PB: 38 (28M,
10F); 43 (9)
2.4 g/d or
1.2 g/d NAC or
PB for 8 wk
DBPC parallel Quantitative
levels of BE,
BSCS, CSSA,
days to relapse
No signiﬁcant
effect;
improved BSCS,
CSSA, days to
relapse only in
initially
abstinent
individuals
Gastrointestinal
AE, headaches,
dizziness,
insomnia
1b/0.5
Methamphetamine
Grant et al.
(2010)
NAC: 14 (8M,
6F); 37.2 (8.2)
PB: 17 (14M,
3F); 36.1 (6.6)
Up to 2.4 g/d
NAC + 200 mg
Naltrexone or
PB for 8 wk
DBPC parallel Penn Craving
Scale, CGI, UDS,
frequency of
use
No signiﬁcant
differences
None 2b/0
Mousavi et al.
(2015)
32 (26M, 6F);
29.2 (4.9)
1.2 g/d NAC or
placebo for
4 wk
DBPC crossover CCQ-Brief,
daily use, UDS,
side effects
Signiﬁcant
improvement
on NAC during
treatment but
no carryover
effects
Not signiﬁcant 2b/0.5
Nicotine
Bernardo et al.
(2009)
Nicotine,
alcohol and
caffeine in
BPAD
NAC: 38 (15M,
23F); 44.6
(11.2)
PB: 37 (15M,
22F); 46.6
(13.8)
1–2 g NAC or
PB for 24 wk
DBPC parallel CGI-SU
(alcohol,
tobacco,
caffeine)
No change in
alcohol and
tobacco use;
signiﬁcant
decrease in
caffeine use in
NAC group at
2 wk
NR 1b/0
Knackstedt
et al. (2009)
NAC: 14 (9M,
5F); 51.3 (10.1)
PB: 15 (10M,
5F); 48.6 (10.5)
2.4 g/d NAC or
PB for 4 wk
DBPC parallel Daily use, CO
levels,
QSU-Brief
(craving),
MNWS
(withdrawal)
No signiﬁcant
differences
NR 2b/0
Schmaal et al.
(2011)
NAC: 10 (42%
M);  21.4 (2.07)
PB: 12 (40% M);
20.25 (1.14)
3.6 g/d NAC or
PB for 3 days
and 1.8 g the
4th day
DBPC parallel QSU-Brief
(craving),
MNWS
(withdrawal),
VAS reward
Reduced
MNWS, VAS
reward; no
effect on
craving
Mild stomach
problems
2b/0.5
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Table  4 (Continued)
Study Participants
# Group (M,  F);
age (SD)
Treatment Study design Outcome
measure
Effect of NAC AE Level/point
Grant et al.
(2014)
28 (23M, 5F);
47.6 (10.9)
NAC: 13
PB: 15
1.2–3.0 g/d
NAC or PB for
12 wk
DBPC parallel Fagerström test
for nicotine
dependence,
HDRS, HARS at
6, 12 and 24 wk
Improvement
at 6 wk but not
at 12 and 24 wk
NR 2b/0.5
McClure et al.
(2014)
Cigarette
smokers from
Gray et al.
(2012); 32M,
36F; 18.8 (1.4)
NAC: 34
PB: 34
2.4 g/d NAC or
PB for 8 wk
DBPC parallel Cigarettes/day;
QSU-Brief;
modiﬁed FTQ
No signiﬁcant
differences
NR 2b/0
Prado et al.
(2015)
Treatment
resistant
tobacco use
disorder
NAC: 17 (7M,
10F); 51.9
(7.02)
PB: 14 (2M,
12F); 50.8
(11.8)
3  g/d NAC or PB
for 12 wk
DBPC parallel Cigarettes/day,
CO levels, quit
rates, HDRS
Signiﬁcant
difference in all
outcomes
Not signiﬁcant 2b/1
Pathological gambling
Grant et al.
(2007)
NAC: 6; gender
and age NR
PB: 7; gender
and age NR
1.8 g/d NAC or
PB for 6 wk
DBPC parallel PG-YBOCS Reduced
PG-YBOCS but
not statistically
signiﬁcant
Mild ﬂatulence 2b/0
Grant et al.
(2014)
28 (23M, 5F);
47.6 (10.9)
NAC: 13 PB: 15
1.2–3.0 g/d
NAC or PB for
12 wk
DBPC parallel PG-YBOCS,
HDRS, HARS at
6, 12 and 24 wk
No effect at 6
and 12 wk but
improved
PG-YBOCS at
24 wk
NR 2b/0.5
Uncontrolled studies
Cannabis
Gray et al.
(2010)
Cannabis
dependent: 24
(18M, 6F); 19
(0.16)
2.4 g/d NAC for
4 wk
Open label Daily
marijuana use,
MCQ, urine
cannabinoid
levels
Signiﬁcant
decrease over 4
weeks in use
and cravings.
No change in
urine
cannabinoid
levels
Mild–moderate
AE in 63% –
abdominal
discomfort,
muscle aches,
insomnia,
headaches,
runny nose,
nausea,
restlessness,
dizziness
4/0.5
Cocaine
Mardikian et al.
(2007)
N = 23 (22M,
1F); 40 (1.4)
1.2–3.6 g/d
NAC for 28 days
Open label Cocaine use,
side effect,
CSSA
Reduced CSSA
and cocaine use
Pruritus,
headache,
ﬂatu-
lence/diarrhea,
abdominal
cramps, local
rash, fatigue,
elevated BP,
sweating, chest
pain, dizziness
4/1
Pathological gambling
Grant et al.
(2007)
N = 27 (15M,
12F); 50.8
(12.1)
Up to 1.8 g/d
NAC for 8 wk
Open label PG-YBOCS,
G-SAS, CGI, SDS
Reduced
PG-YBOCS
Mild ﬂatulence 4/1
AE, adverse effects; BE, benzoylecgonine; BP, blood pressure; BPAD, bipolar disorder; BSCS, Brief Substance Craving Scale; CCQ-Brief, Cocaine Craving Questionnaire-Brief;
CSSA,  Cocaine Selective Severity Assessment; CGI, Clinical Global Impression; CO, carbon monoxide; DBPC, Double Blind Placebo Control Trial; FTQ, Fagerström Tolerance
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suestionnaire; G-SAS, Gambling Symptom Assessment Scale; HARS, Hamilton An
uestionnaire; MNWS,  Minnesota Nicotine Withdrawal Scale; NR, not reported;
ompulsive Scale; QSU, Questionnaire of Smoking Urges; SDS, Sheehan Disability S.1.1.1. Cannabis. A large DBPC trial (N = 116; LOE 1b) which
reated cannabis dependent adolescents and young adults with
.4 g/day of NAC or placebo along with brief weekly cessation coun-
eling and contingency management for 8 weeks demonstratedRating Scale; HDRS, Hamilton Depression Rating Scale; MCQ,  Marijuana Craving
dds ratio; PB, placebo; PG-YBOCS, Pathological Gambling-Yale-Brown Obsessive
U, substance use; UDS, Urine Drug Screen; VAS, Visual Analog Scale.that signiﬁcantly more NAC treated individuals demonstrated a
negative urine cannabinoid tests (Gray et al., 2012). Secondary out-
come measure of self-reported days of cannabis use favored NAC
but was not statistically signiﬁcant. Further analysis performed on a
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ubset of the participants (N = 89) found a decrease in self-reported
arijuana craving in both groups, but no statistically signiﬁcant
ifference between groups (Roten et al., 2013). A small open-label
ncontrolled study (N = 24; LOE 4) found signiﬁcant improvements
n number of days used and cravings, but no signiﬁcant changes
ere seen in urine cannabinoid levels (Gray et al., 2010).
Thus, there is one LOE 1b study that suggests partial improve-
ent in clinical measures of cannabis use. This provides a GOR of
, but this must be considered carefully as it is not clear how NAC
ffects cannabinoid metabolism. If NAC hastens the elimination of
annabinoid then it might be more likely for an individual to have a
egative urine test. In addition, concurrent use of psychotherapeu-
ic intervention along with NAC treatment could have decreased
he individual effect of NAC on cannabis use. Further studies will
e needed to investigate these possibilities.
.1.1.2. Cocaine. A three-arm DBPC (N = 111; LOE 1b) treated
reatment-seeking cocaine dependent adults with NAC 2.4 g/day,
AC 1.2 g/day or placebo for 8 weeks (LaRowe et al., 2013). No
igniﬁcant effects were found in any of the outcome measures –
uantitative levels of benzoylecgonine in urine, a cocaine metabo-
ite, Brief Substance Craving Scale (BSCS) and Cocaine Selective
everity Assessment (CSSA). A positive effect of NAC on the BSCS,
SSA and days to relapse was found in a very small subgroup of
ndividuals who were abstinent at the beginning of the trial. Addi-
ionally, riboﬂavin, the compound added to both the NAC and the
lacebo to measure compliance, is a co-factor for the enzyme glu-
athione peroxidase – an enzyme that is essential in glutathione
ntioxidant metabolism and one of the metabolic targets of NAC.
hus, it is possible the addition of riboﬂavin to the treatment cap-
ules in both groups could have reduced any effect of NAC. The
esults were mixed for two other small controlled trials (N = 15, 6;
OE 2b) (LaRowe et al., 2007; Amen et al., 2011). A small 4 week
pen-label uncontrolled safety study (N = 23; LOE 4) found that NAC
igniﬁcantly reduced self-reported craving and abstinence scores
n the CSSA, the number of use days and total dollar amount spent
n use (Mardikian et al., 2007).
Thus, with at least one LOE 1b study a GOR of B is assigned to NAC
or treatment for cocaine addiction symptoms. However, the largest
tudy to date was overall negative and other controlled studies
ere rather small. This limits the conﬁdence to which these results
an be generalized. Thus, it is clear that other larger well-designed
ontrolled clinical studies are needed to follow-up on these initial
tudies.
.1.1.3. Methamphetamine. One small sized DBPC trials (N = 31;
OE 2b) compared progressive increasing doses of NAC (up to
.4 g/day) along with Naltrexone (up to 200 mg/day) vs. placebo
or 8 weeks in non-treatment-seeking subjects with metham-
hetamine dependence (Grant et al., 2010). The study found no
tatistical difference in the Penn rating scale for craving, frequency
f use, urine toxicology results or Clinical Global Impression –
everity (CGI-S). This study was limited by a high dropout rate.
nother recent small DBPC cross over trial (N = 32; LOE 2b) found
igniﬁcant decrease in Cocaine Craving Questionnaire-Brief (CCQ-
rief) scores in the NAC (1.2 g/day) group when compared to
lacebo among the 23 treatment seeking completers. The effect was
o longer signiﬁcant when cross treatment was done with placebo
ndicating NAC’s limited effect on relapse prevention (Mousavi
t al., 2015).
Thus, there are two LOE 2b trials studying the effect of NAC on
ethamphetamine dependence resulting in a GOR of B, but thesetudies were inconsistent, so an unequivocal recommendation for
he use of NAC treatment for methamphetamine dependence can-
ot be made at this point and further larger controlled trials are
eeded.avioral Reviews 55 (2015) 294–321
3.1.1.4. Nicotine. A medium sized DBPC trial (N = 75; LOE 1b)
treated individuals with BPAD I and II with 1–2 g/day NAC or
placebo for 24 weeks and measured change in tobacco, alcohol
and caffeine use. There was a signiﬁcant decrease in caffeine use
in the NAC group at 2 weeks, but not at any other visit. The biggest
limitation of this study was  that the clinical cohort was  individu-
als with BPAD and the overall rates of substance use disorder in
this cohort were low. This affected the power of this study spe-
ciﬁc to substance use disorder and might have affected the overall
results (Bernardo et al., 2009). An analysis of the cigarette smokers
in a DBPC study (N = 68; LOE 2b) on cannabis cessation (Gray et al.,
2012) demonstrated no effect of 2.4 g/day of NAC on the number
of cigarettes smoked per day on Smoking Urges-Brief or Modiﬁed
Fagerström Tolerance Questionnaire scores (McClure et al., 2014).
Three small sized trials (N = 29, 22, 28; LOE 2b) reported either neg-
ative or mixed results on use of NAC in nicotine use disorder (Grant
et al., 2014; Knackstedt et al., 2009; Schmaal et al., 2011). In a recent
pilot study (N = 34; LOE 2b), there was a signiﬁcant reduction in
both the number of cigarettes used and exhaled carbon monox-
ide, which was complimented by higher cessation rates in the NAC
(47.1%) than the placebo (21.4%) group (Prado et al., 2015). Overall
there is one LOE 1b and at least two  LOE 2b studies resulting in a
GOR of B but there is little evidence of effectiveness of the NAC for
nicotine addiction. The studies which demonstrated some differ-
ences showed inconsistent effects. Thus, a recommendation for the
use of NAC for nicotine cannot be made at this time.
3.1.1.5. Pathological gambling. A small 8 week open-label uncon-
trolled trial (N = 27; LOE 4) treated individuals with pathological
gambling with 1.8 g/day of NAC for 8 weeks and found
improvement in the Pathological Gambling-Yale-Brown Obsessive
Compulsive Scale (PG-YBOCS), Gambling Symptom Assessment
Scale (G-SAS), CGI and Sheehan Disability Scale (SDS) (Grant et al.,
2007). A few responders from this open-label trial completed a 6
week DBPC withdrawal trial (N = 13; LOE 2b) but results were not
statistically signiﬁcant. The selection of responders and the with-
drawal study design may  have reduced the effect that could have
been detected from the controlled study. For example, by selecting
responders, the study may have selected a higher number of indi-
viduals with a placebo response. Another small DBPC trial (N = 28;
LOE 2b) did not ﬁnd improvement in any outcome measures during
12 weeks of treatment phase of the study but showed improvement
at 24 week follow-up (Grant et al., 2014). However, only 11 indi-
viduals completed the follow-up visits, suggesting a signiﬁcant bias
due to high dropouts. Thus, with two  LOE 2b studies, the GOR is B
but there is only limited evidence for the effectiveness of NAC for
gambling addiction.
3.1.1.6. Addiction overall. Overall, the evidence for NAC as a treat-
ment for addiction is rather limited. Although several controlled
studies were positive for cocaine, the largest and most meticulously
performed study was only positive for a small subset of partici-
pants that were abstinent at the beginning of the trial. There is
some evidence for cannabis but this is limited due to inconsistent
ﬁndings. Other addictions have limited evidence that NAC is a use-
ful treatment. However, many of the studies conducted were rather
preliminary in nature and hence making recommendations for or
against the use of NAC in addiction is somewhat preliminary.
3.1.2. Alzheimer’s disease
In the largest DBPC trial to date (N = 43; LOE 2b), patients with
probable AD who  were treated with either 50 mg/kg/day of NAC
or placebo for 24 weeks showed improvement in some, but not
all cognitive testing (Adair et al., 2001). An attempt was made
to do a small DBPC using 0.6 g NAC with 400 g folic acid, 6 mg
vitamin B12, 30 IU -tocopherol, 400 mg  S-adenosyl methionine
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nd 500 mg  acetyl-l-carnitine daily vs. placebo for 9 months in
2 institutionalized patients with moderate to late-stage proba-
le AD (Remington et al., 2009). Unfortunately everyone in the
lacebo group dropped-out by 6 months, making the study a small
ncontrolled case-series (N = 6; LOE 4). This treatment delayed the
ecline in the Dementia Rating Scale-2 (DRS-2) and Clock Drawing
est (CLOX-1) tests and resulted in improvements in the Neu-
opsychiatric Inventory and AD Cooperative Study – Activities of
aily Living. Another case report (N = 1; LOE 4) described a man
ith probable AD and hyperhomocysteinemia who demonstrated
mpressive clinical improvements when NAC was added to hydrox-
cobalamin and 5 mg  folinic acid (McCaddon and Davies, 2005).
Since there is only one LOE 2b trial, the GOR is C for AD. The
esults of studies are mixed and high-quality controlled studies
ould be very helpful in documenting a potential therapeutic effect
f NAC in AD (Table 5).
.1.3. Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenera-
ive disorder, caused by degeneration of central and peripheral
otor neurons (Williams and Windebank, 1991). The largest DBPC
N = 110; LOE 1b) failed to show any beneﬁt of subcutaneous
0 mg/kg/day of NAC in survival and/or disease progression when
ompared to placebo in individuals with ALS (Louwerse et al., 1995).
imilarly another small sized case control study (N = 36; LOE 3b)
oncluded no beneﬁt in survival with NAC along with other antiox-
dants (Vyth et al., 1996). There are two uncontrolled open label
tudies with mixed results (N = 51, 11; LOE 4) (De Jong et al., 1987;
üther and Struppler, 1987). With one LOE 1b study the GOR for
LS is B but since 100% of the controlled studies and 75% of overall
tudies were negative, NAC does not seem to be a recommended
reatment option for increasing survival in ALS at this time (Table 6).
.1.4. Anxiety
One case study (N = 1; LOE 4) reported signiﬁcant improvement
s evident by drop in CGI-S from 5 to 2 after 8 week treatment
ith NAC in a 17 yo male with generalized anxiety disorder and
ocial phobia who previously failed both multiple selective sero-
onin reuptake inhibitors and cognitive behavioral therapy (Strawn
nd Saldana, 2012). As there is only one case report, a GOR D is
ssigned and hence it is difﬁcult to make any recommendations for
AC treatment for anxiety at this point (Table 7).
.1.5. ADHD
A small sized DBPC study (N = 24; LOE 2b) examined the effect of
AC (2.4 g/day or 4.8 g/day), compared to placebo on ADHD within
 systemic lupus erythematosus (SLE) population (Garcia et al.,
013). NAC reduced ADHD symptoms as measured by the ADHD
elf-Report Scale Symptom Checklist (ASRS). With one LOE2b
tudy, a GOR of C is assigned but this evidence must be tempered
ith the fact that the study population suffered from SLE and thus
annot be generalized as a treatment for typical ADHD (Table 8).
.1.6. Autism
In a small sized DBPC study (N = 29; LOE 2b), Aberrant Behavior
hecklist Irritability Subscale (ABC-I) scores signiﬁcantly decreased
ver the study period in the NAC group as compared to the placebo
roup (Hardan et al., 2012). Although other secondary outcomes
mproved, no signiﬁcant improvement was found in the CGI-
mprovement (CGI-I) or CGI-S. In another small sized DBPC study
N = 40; LOE 2b), the NAC add-on to risperidone group showed a
ecrease in ABC-I as compared to the placebo group but did not
ffect any of the core autism symptoms. It should be noted that the
reatment group started out with a signiﬁcantly higher ABC-I at
he beginning of the trial (Ghanizadeh and Moghimi-Sarani, 2013).
imilar ﬁndings were seen in a recent 10 week small sized DBPCavioral Reviews 55 (2015) 294–321 301
trial (N = 40; LOE 2b) on NAC treatment adjunctive to risperidone
on irritability and hyperactivity subscales (Nikoo et al., 2015).
Two  case studies (LOE 4) reported improvements in core and
associated ASD behaviors with NAC treatment. (Ghanizadeh and
Derakhshan, 2012; Marler et al., 2014). Given that there are three
LOE 2b studies of autism, a GOR of B is given to NAC for the
treatment in children with autism. Clearly NAC is a promising treat-
ment for irritability in children with autism. Larger clinical trials
are needed to conﬁrm these ﬁndings and potentially investigate
whether other core or associated autism symptoms may respond
to NAC treatment (Table 9).
3.1.7. Bipolar disorder
Several controlled and uncontrolled studies have investigated
NAC in treating and preventing symptoms during the maintenance
phase of BPAD (Table 10). In the ﬁrst multicenter DBPC trial (N = 75;
LOE 1b), when compared to placebo, the NAC group demonstrated
a signiﬁcant improvement on the Montgomery–Asberg Depression
Scale (MADRS), Bipolar Depression Rating Scale (BDRS) and nine
out of 12 secondary outcome measures in individuals in the main-
tenance phase of BPAD (Berk et al., 2008b). However, the study
failed to show any signiﬁcant differences between the two groups
in the frequency of or latency to new episodes of either depression
or mania (Berk et al., 2008b).
Several subgroup analyses of the abovementioned study have
been done to examine other outcome measures. No intergroup
differences were found on cognitive outcomes examined in one
subgroup analysis (N = 46) using digit span, word learning, trail
making and verbal ﬂuency (Dean et al., 2012). The interaction
between symptoms, functioning level and medical comorbidities
using a self-reported checklist was examined in another subgroup
analysis (N = 74) and showed advantage of NAC treatment in func-
tioning over the placebo treatment in individuals with medical
comorbidities as compared to individuals without medical comor-
bidities (Magalhaes et al., 2012).
A small subgroup analysis (N = 17) of individuals who had a
major depressive episode at baseline, showed that NAC treatment
signiﬁcantly improved measures of symptom severity, functioning,
quality of life and response rate at the end of 24 weeks (Magalhaes
et al., 2011b). In another subgroup analysis (N = 14) of individu-
als who had BPAD II, changes were more pronounced for every
outcome including Young Mania Rating Scale (YMRS) in the NAC
treatment group, as compared to the placebo group (Magalhaes
et al., 2011a). Another small subgroup analysis examined individ-
uals (N = 15) with a manic or hypomanic episode at baseline and
reported improvement in YMRS in the NAC group and a worsen-
ing of BDRS in the placebo group. More participants in NAC group
had complete symptom remission although it was  not statistically
signiﬁcant (Magalhaes et al., 2013).
Subsequent studies focused speciﬁcally on depressive symp-
toms of BPAD. A large 8 week open-label run-in (N = 149; LOE  4) to
a DBPC trial included individuals with BPAD and a recent episode
of moderate depression. The study showed robust improvement in
BDRS, functioning and quality of life on NAC add-on to usual treat-
ment (Berk et al., 2011a, 2011b). Participants in the above study
with a MADRS ≥ 12 at baseline were randomized (N = 149; LOE 1b)
to NAC or placebo add-on treatment for 24 weeks. The primary
outcome measure, latency to a mood episode, was not signiﬁcantly
different between the treatment and placebo groups (Berk et al.,
2012).
Thus, there are two  LOE 1b studies in BPAD with one of the two
positive for NAC as an effective treatment for BPAD symptoms,
resulting in a GOR of A. The negative study was a withdrawal
study which measured time to new mood episode. This could
suggest that the initial 8-week open-label treatment was  enough
time to optimally reverse physiological processes and that further
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Table 5
Alzheimer’s disease (AD).
Study Participants
# Group (M,  F);
age in year (SD)
Treatment Study design Outcome
measure
Effect of NAC AE Level/point
Controlled studies
Adair et al.
(2001)
NAC: 23
PB: 20
Age and gender
NR
50 mg/kg/d
NAC in 3
divided doses
for 24 wk  or PB
DBPC parallel MMSE, ADL,
cognitive
battery
Improvement
in some
cognitive tests
Transient
headache
2b/0.5
Uncontrolled studies
McCaddon and
Davies
(2005)
65 yo M with
probable AD
and hyperho-
mocysteinemia
0.6 g/d NAC +
hydroxocobalamin
and 5 mg
folinic acid
Case report Symptoms Less agitated;
improved
recognition,
compliance,
memory and
communica-
tion
NR 4/1
Remington
et al. (2009)
Institutionalized
moderate-to-
late stage AD
NAC: 6
PB: 6, all
dropped out by
6 months
0.6 g
NAC + other
vitamins for
9  mo  or PB for
6 mo
Case series DRS-2, CLOX-1,
NPI, ADCS-ADL
Improved NPI
and ADL.
Slower CLOX-1
and DRS-2
decline
NR 4/1
A , Acti
D ntesti
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tDCS-ADL, Alzheimer’s Disease Cooperative Study – Activities of Daily Living; ADL
RS-2,  Dementia Rating Scale-2; CLOX-1, Clock Drawing Executive Test; GI, gastroi
ot  reported; PB, placebo.
rolonged treatment was not necessary to provide an advantage of
he NAC treatment. However, the primary outcome measure in the
ithdrawal study was not signiﬁcant in the other large DPBC study,
uggesting that time to new mood episode is not a clinical charac-
eristic of BPAD that is effectively treated by NAC. This may  indicate
hat NAC may  lessen symptoms of BPAD but may  not affect the
able 6
myotrophic lateral sclerosis (ALS).
Study Participants
# Group (M,  F);
age (SD)
Treatment Study design 
Controlled studies
Louwerse et al.
(1995)
Acetylcysteine:
54 (29M, 25F);
58 (11)
PB: 56 (32M,
24F); 57 (9.6)
50 mg/kg/d SQ
acetylcysteine
or PB for 12 mo
DBPC Parallel 
Vyth et al.
(1996)
ALS: 36
Controls: 107
Age and gender
NR
SQ NAC ± Vit C
and E, NAM,
DTT, DTE for
3–4.2 yr
Case control 
Uncontrolled studies
De Jong et al.
(1987)
ALS: 40
Spinal
muscular
dystrophy: 11
Age and gender
NR
Everyone:
100 ml  of 5%
NAC, SQ/d for
6–24 mo
26 (not stable
on NAC alone):
DTT
10 (hypersensi-
tivity to NAC):
prednisone
Open label 
Küther and
Struppler
(1987)
N = 11 (6M, 5F);
35–68 yo
50 ml  of 5%
NAC, SQ/d and
Vit C for
1–12 mo
Open label 
E, adverse effects; DBPC, Double Blind Placebo Controlled; DTE, dithioerythritol; DTT, d
aneous; Vit, vitamin.vities of Daily Living; AE, adverse effects; DBPC, Double Blind Placebo Controlled;
nal; MMSE, Mini-Mental Status Examination; NPI, Neuropsychiatric Inventory; NR,
frequency of cycling between mood states. Clearly NAC treatment
for BPAD seems promising and deserves further investigation.3.1.8. Depressive disorder
A large randomized controlled trial (N = 252; LOE 1b) in individ-
uals with major depressive disorder (MDD) and MADRS score ≥ 18
Outcome
measure
Effect of NAC AE Level/point
Survival No signiﬁcant
difference in
survival or
reduction in
disease
progression
NR 1b/0
Survival No effect on
survival
Gastric pain,
nausea,
abdominal
discomfort
3b/0
Increased,
equal or drop
less than 10% in
Norris score,
vital chest
capacities
62% were
stable at 6 mo
and 52% at
24 mo
Hypersensitivity 4/1
Contracture,
muscle
strength,
Norris score,
vital capacity
No signiﬁcant
difference
Pain, swelling,
SC granuloma,
and abscess at
the injection
site,
rhinorrhea, leg
edema, allergic
reaction
4/0
ithiothreitol; NAM, N-acetylmethionine; NR, not reported; PB, placebo; SQ, subcu-
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Table  7
Anxiety.
Study Participants
# Group (M,  F);
age (SD)
Treatment Study design Outcome
measure
Effect of NAC AE Level/point
Uncontrolled Studies
Strawn and
Saldana
(2012)
17 yo M with
generalized
anxiety and
1.2 g/d NAC for
4 wk then
2.4 g/d for 4 wk
Case report CGI; subjective
anxiety levels
Improved CGI;
decreased
subjective
None 4/1
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E, adverse effects; CGI, Clinical Global Impression.
howed improvement in multiple outcome measures – in the NAC
roup when compared to placebo add on treatment to usual treat-
ent for 12 weeks (Berk et al., 2014). There is also a case series
N = 2; LOE 4) that showed successful and sustained improvement
f depressive symptoms on NAC augmentation in two  patients with
DD  who had responded only partially to a trial of monoamine
xidase inhibitors (MAOI) tranylcypromine (Carvalho et al., 2013)
Table 11).
With one LOE 1b study, the GOR is B. Since the randomized
ontrolled trial was not positive for all the outcome measures,
he recommendations for NAC treatment for MDD  is still mixed
nd further controlled studies and longer follow-up for assessing
onsistent improvement are needed. Overall NAC seems to be a
romising treatment option for mood disorders. It has shown to
ave positive effect on mood in an unrelated RCT that studied NAC
or idiopathic pulmonary ﬁbrosis, and found no beneﬁt for that
ndication. However, on a measure of well-being, the SF 36, there
ere signiﬁcant between group differences favoring the NAC group
Martinez et al., 2014). The SF 36 has shown a tight correlation with
ore traditional mood scales (Elliott et al., 2003).
.1.9. Epilepsy
All the studies have been in progressive myoclonus epilepsy,
nverricht–Lundborg Disease (ULD) (Table 12). ULD is an autoso-
al  recessive neurodegenerative disorder (21q22.3) that typically
egins between 6 and 15 years of age characterized by myoclonus
nd tonic–clonic seizures, followed by the development of
ysarthria, cognitive dysfunction and ataxia. Most patients have
arked impairment in daily life functioning and marked disability
Lehesjoki and Koskiniemi, 1998). In ﬁrst case series (N = 4; LOE
) of use of adjunctive treatment with NAC in ULD, four siblings
ere treated with 4–6 g/day of NAC over 26–30 months for ULD
nd showed remarkable improvement in symptoms and basic
aily functioning (Hurd et al., 1996). Similar responses to 6 g/day
AC were seen in a 40-year-old male with ULD with marked
mprovement in walking, myoclonus, generalized seizures, talking
nd daily living skills (N = 1; LOE 4). Symptoms clearly worsened
hen he refused his medications for 1 week when parents were
n vacation. Improvement was seen back within 2 days as soon
s he restarted his medicines and was sustained for 10 month of
able 8
ttention-deﬁcit hyperactivity disorder (ADHD).
Study Participants
# Group (M,  F); age
(SD)
Treatment Study desi
Controlled studies
Garcia et al. (2013) Participants with
ADHD and SLE; 45.9
(1.8)
NAC, 2.4 g/d: 9
NAC, 4.8 g/d: 9
PB: 6
Controls: 22; 48.0 (1.5)
2.4 g/d or
4.8 g/d or PB for
3 mo
DBPC – thr
arms
SRS, ADHD Self Report Scale; AE, adverse effects; DBPC, Double Blind Placebo Controlledanxiety
follow-up (Selwa, 1999). Another case series (N = 5; LOE  4) also
showed positive response to 4–6 g/day NAC in the majority of the
ﬁve cases of progressive myoclonic epilepsies (four with ULD and
one with Lafora Body disease) (Ben-Menachem et al., 2000). Mixed
response ranging from dramatic improvement in some individuals,
partial or failed improvement in some and signiﬁcant side effects
including possible neutropenia and sensorineural hearing loss in
some were reported in a subsequent case series (N = 4; LOE-4)
(Edwards et al., 2002). With four case studies/series (LOE 4),
the GOR is C. The results of the case series are mixed and some
serious adverse events are mentioned in these studies therefore
the recommendation for use of NAC in progressive myoclonus
epilepsy is mixed and further controlled studies are needed.
3.1.10. Impulse control disorder
Several controlled and uncontrolled trials were conducted on
various impulse control disorders including trichotillomania, skin
picking disorder and nail biting disorder (Table 13).
3.1.10.1. Nail biting. A DBPC study (N = 42; LOE 2b) on nail-biting
in children showed greater increase in nail length after 1 month of
treatment with NAC compared to placebo but this difference was
not signiﬁcant at the end of second month (Ghanizadeh et al., 2013).
Two case series (N = 4; LOE 4) reported improvement in nail biting
frequency with NAC (Berk et al., 2009; Odlaug and Grant, 2007).
Thus with one LOE 2b and two  LOE 4 studies, the GOR is C but con-
sidering the results of controlled trial was not consistently positive
over time, there is only limited evidence on effectiveness of NAC
on nail biting disorder and further controlled studies are required.
3.1.10.2. Skin picking. An interesting open-label prospective case-
series (N = 35; LOE 4) of individuals with Prader–Willi syndrome
demonstrated a signiﬁcant improvement in skin-picking symp-
toms and skin lesions in the majority of individuals with 12 week
NAC treatment (Miller and Angulo, 2014). Several adult case series
(N = 5; LOE 4) have reported decrease in the frequency of skin pick-
ing behavior with NAC treatment (Grant et al., 2012; Odlaug and
Grant, 2007; Silva-Netto et al., 2014). With four LOE  4 studies, the
GOR is C. All the studies showed positive effect so NAC seems like a
gn Outcome
measure
Effect of NAC AE Level/point
ee ASRS Improved ASRS
Scores
None 2b/1
.
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Table 9
Autism.
Study Participants
# Group (M,  F);
age in year (SD)
Treatment Study design Outcome
measure
Effect of NAC AE Level/point
Controlled studies
Hardan et al.
(2012)
NAC: 14 (12M,
2F); 7 (2.1)
PB: 15 (15M,
0F); 7.2 (2.2)
0.9 g NAC:
1×/d × 4 wk
then
2×/d × 4 wk
then
3×/d × 4 wk or
PB
DBPC parallel Primary: ABC
Irritability
Secondary:
ABC-
Stereotype,
SRS, RBS-R, CGI
Improved ABC
Irritability, SRS
cognition,
autism
mannerisms
and RBS-R
stereotypies
but no effect on
other SRS
subscales or
CGI
Gastrointestinal
AE
2b/0.5
Ghanizadeh
and
Moghimi-
Sarani
(2013)
NAC: 20 (13M,
7F); 8.8 (3.1)
PB: 20 (12M,
8F); 7.9 (2.4)
Risperidone
with add-on
1.2 g NAC/d or
PB for 8 wk
DBPC parallel ABC-
Irritability,
lethargy, social
withdrawal,
stereotype
behavior,
hyperactivity,
noncompliance
and
inappropriate
speech
subscale
Signiﬁcant
improvement
in irritability
only and no
change in other
secondary
outcome
measures
Not signiﬁcant 2b/0.5
Nikoo et al.
(2015)
NAC: 20 (16M,
4F); 7.5 (2.6)
PB: 20 (17M,
3F); 7.6 (2.6)
Risperidone
with add-on
0.6–0.9 g/d
NAC or PB for
10 wk
DBPC parallel ABC-
Irritability,
lethargy, social
withdrawal,
stereotype
behavior,
hyperactivity,
noncompliance
and
inappropriate
speech
subscale at 5
and 10 wk
Signiﬁcant
improvement
in irritability
and
hyperactivity
subscale but no
change in other
secondary
outcome
measures
Not signiﬁcant 2b/0.5
Uncontrolled studies
Ghanizadeh
and
Derakhshan
(2012)
8 yo M with
autism,
nail-biting,
hyperactivity
and
inattentiveness
0.8 g NAC/d for
30 days
Case report VAS for social
interactions,
communica-
tion, verbal
skills and
aggression
Improvement
on all VAS
measures,
improved
nail-biting,
hyperactivity
and
inattentiveness
Mild abdomen
pain
4/1
Marler et al.
(2014)
4 yo M with
severe
self-injurious
behavior
0.45 g/d
titrating to
1.8 g/day over
3 wk
Case report Frequency and
severity of
self-injurious
behavior
Improvement
in
self-injurious
behavior
None 4/1
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itive only at one time point. However, there were some limitationsBC, Aberrant Behavior Checklist; AE, adverse effects; CGI-I, Clinical Global Impre
lacebo Controlled; NAC, N-acetylcysteine; NR, not reported; PB, placebo; RBS-R, R
cale.
romising treatment option for skin picking but further controlled
tudies are needed.
.1.10.3. Trichotillomania. In a medium sized DBPC trial (N = 50;
OE 1b), signiﬁcant improvements were found on the Mas-
achusetts General Hospital Hair Pulling Scale, the Psychiatric
nstitute Trichotillomania Scale and the CGI in participants who
eceived NAC as compared to the placebo group (Grant et al., 2009).
n another DBPC trial (N = 39; LOE 2b), no signiﬁcant differences in
mprovement between NAC and placebo groups were found in chil-
ren and adolescents with trichotillomania (Bloch et al., 2013). The
uthors suggest that their study ﬁndings may  differ from previous
tudies due to a younger aged sample or more severe trichotilloma-
ia symptoms among the placebo group in their study. Four case
eries (N = 6; LOE 4) in adults reported improved hair growth with– Improvement; CGI-S, Clinical Global Impression – Severity; DBPC, Double Blind
tive Behavior Scale-Revised; SRS, Social Responsiveness Scale; VAS, Visual Analog
NAC (Odlaug and Grant, 2007; Rodrigues-Barata et al., 2012; Silva-
Netto et al., 2014; Taylor and Bhagwandas, 2014). Thus, with one
LOE 1b, one LOE 2b and four LOE 4 studies, the GOR is B. The results
however are mixed as only one out of two  controlled trials was  pos-
itive for improvement. Larger clinical trials are needed to conﬁrm
the effectiveness of NAC in trichotillomania.
3.1.10.4. Impulse control disorder overall. The GOR  is B given the one
LOE 1b study but this must be tempered with the fact that one other
DBPC study did not ﬁnd positive results and another DBPC was pos-to the negative DBPC studies, and seven uncontrolled studies have
documented positive results. Thus, further studies will be needed
to help clarify the role of NAC in impulse control disorders as NAC
may be a promising treatment.
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Table  10
Bipolar disorder (BPAD).
Study Participants
# Group (M,  F); age
in year (SD)
Treatment Study design Outcome
measure
Effect of NAC AE Level/point
Controlled studies
Berk et al.
(2008b)
NAC: 38 (15M,
23F); 44.6 (11.2)
PB: 37 (15M, 22F);
46.6 (13.8)
1 g NAC BID for
24 wk or PB
DBPC parallel MADRS, BDRS,
YMRS, CGI,
GAF, SOFAS,
SLICE-LIFE,
LIFE-RIFT,
Q-LES-Q
Moderate-to-
large effect on
MADRS and
BDRS
Changed
energy,
headaches,
increased joint
pain,
heartburn, 3
serious AE
1b/1
Magalhaes
et al. (2011a)
BPAD II
NAC: 7 (4M, 3F); 43
(29)
PB: 7 (3M, 4F); 52
(54)
Signiﬁcant
improvement
in the YMRS.
More
participants
achieved
remission in
depression and
mania
symptoms
Mild HA in 1,
sweating in 1,
increased thirst
in 1
Magalhaes
et al. (2011b)
BPAD with major
depressive episode
at baseline
NAC: 10 (5M, 5F);
43 (15.39)
PB: 7 (3M, 4F);
42.86 (15.39)
Signiﬁcant
improvement
on MADRS,
BDRS, GAF,
RIFT and
Q-LES-Q.
Signiﬁcantly
more patients
with treatment
response
Mild HA in 3,
diarrhea and
abdominal pain
in 2
Magalhaes
et al. (2013)
BPAD with manic
or hypomanic
episodes at
baseline
NAC: 8 (4M, 4F); 50
(20)
PB: 7 (3M, 4F); 38
(36)
Signiﬁcant
improvement
in YMRS within
NAC group;
more symptom
remission
1 NAC patient
withdrew due
to AE
Magalhaes
et al. (2012)
BPAD with medical
comorbidities
NAC: 38 (15M, 23
F); 44.6 (11.2)
PB: 36 (14M, 22F);
46.6 (13.8)
Self-reported
medical
comorbidities,
MADRS, BDRS,
YMRS, CGI,
GAF, SOFAS,
SLICE/LIFE,
LIFERIFT,
Q-LES-Q
Only all the
functional
outcomes were
better with
medical
comorbidity
NR
Dean et al.
(2012)
NAC: 21 (8M, 13F);
44.6 (12.5)
PB: 25 (10M, 15F);
46.4 (13.1)
Digit span,
word learning,
trail making,
verbal ﬂuency
No effect NR
Berk et al.
(2012)
BPAD with
depressive
symptoms at
baseline
(MADRS ≥ 12)
NAC: 76 (16M,
60F); 47.1 (10.9)
PB: 73 (32M, 41F);
44.4 (11.8)
1 g NAC BID for
24 wk or PB
DBPC
withdrawal
MADRS, BDRS,
YMRS, CGI,
GAF, SOFAS,
SLICE/LIFE,
LIFERIFT,
Q-LES-Q
No effect NR 1b/0
Uncontrolled studies
Berk et al.
(2011a,
2011b)
BPAD with
depressive
symptoms at
baseline
(MADRS ≥ 12)
149 (48M, 101F);
45.8 (11.4)
1 g NAC BID for
8 wk
Open label BDRS, MADRS,
YMRS, CGI,
GAF, SOFAS,
SLICE/LIFE,
LIFERIFT,Q-
LES-Q
Signiﬁcant
improvement
in all outcome
measures
NR 4/1
AE, adverse effects; BDRS, Bipolar Depression Rating Scale; CGI-S, Clinical Global Impression Severity Scale; DBPC, Double Blind Placebo Controlled; GAF, Global Assessment
of  Functioning; LIFE-RIFT, Longitudinal Interval Follow-up Evaluation Range of Impaired Functioning Tool; MADRS, Montgomery–Asberg Depression Scale; NR, not reported;
PB,  placebo; Q-LES-Q, Quality of Life Enjoyment and Satisfaction Questionnaire; SLICE/LIFE, Streamlined Longitudinal Interview Clinical Evaluation from the Longitudinal
Interval  Follow-up Evaluation; SOFAS, Social and Occupational Functioning Assessment Scale; YMRS, Young Mania Rating Scale.
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Table 11
Depressive disorder.
Study Participants
# Group (M,  F);
age in year (SD)
Treatment Study design Outcome
measure
Effect of NAC AE Level/point
Controlled studies
Berk et al.
(2014)
MDD
(MADRS ≥ 18)
NAC: 127
(43M, 84F);
49.9 (13.0)
PB: 125 (50M,
75F); 50.5
(12.5)
1 g BID NAC for
12 wk  or PB
add on to usual
treatment
DBPC parallel MADRS, CGI-I,
CGI-S, HARS,
GAF, SOFAS,
SLICE/LIFE,
LIFERIFT,
Q-LES-Q at
12 wk  and 4 wk
after treatment
discontinua-
tion
(16 wk)
No signiﬁcant
effect on
MADRS,
response rate,
remission rate
at 12 wk but
signiﬁcant
effect at 16 wk;
LIFE-RIFT
improved at
12 wk; no
signiﬁcant
change in GAF
and SOFAS
Gastrointestinal
and muscu-
loskeletal
AE
1b/0.5
Uncontrolled studies
Carvalho et al.
(2013)
Severe
treatment
resistant MDD
on tranyl-
cypromine
Case 1: 22 yoM
Case 2: 43 yo F
2 g BID NAC for
8 wk
Case series HDRS and CGI-I Improvement
in and CGI in
both the cases
NR 4/1
AE, adverse effects; CGI-I, Clinical Global Impression Improvement Scale; CGI-S, Clinical Global Impression Severity Scale; DBPC, Double Blind Placebo Controlled; GAF,
Global  Assessment of Functioning; HARS, Hamilton Anxiety Rating Scale; HDRS, Hamilton Depression Rating Scale; LIFE-RIFT, Longitudinal Interval Follow-up Evaluation
Range of Impaired Functioning Tool; MADRS, Montgomery–Asberg Depression Scale; MDD, major depressive disorder; NR, not reported; PB, placebo; Q-LES-Q, Quality of Life
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.1.11. Neuropathy
In a small sized DBPC (N = 14; LOE 2b) trial, 14 stage III colon
ancer receiving adjunctive biweekly oxaliplatin along with ﬂuo-
ouracil/leucovorin chemotherapy were randomized to 1.2 g/day
AC (N = 5) or placebo (N = 9) to see the protective effect of NAC in
he development of common serious adverse effect of oxaliplatin
 grades 3–4 sensory neuropathy. After 12 cycles of chemother-
py, the study showed a signiﬁcant beneﬁt of NAC over placebo
n preventing development of oxaliplatin induced serious sensory
europathy (Lin et al., 2006). One other case report (N = 1; LOE 4)
howed positive response on combination of neuro-protectants –
AC, Levocarnitine and Pyridoxine in a 46-day-old male with acute
ymphoblastic leukemia (ALL) who developed severe vincristine-
nduced peripheral neuropathy (Baker and Lipson, 2010). With
ne LOE 2b and one LOE 4 studies, the GOR is C but considering
he small sample size of the controlled study and use of multiple
ntioxidants in the case study, the data is still limited to pro-
ide any recommendations for use of NAC in anticancer medicines
nduced neuropathy. Further large controlled studies are required
Table 14).
.1.12. Obsessive compulsive disorder
A 12 week DBPC trial (N = 48; LOE 2b) treated individuals with
CD on a selective serotonin reuptake inhibitor with either placebo
r NAC. Results showed signiﬁcant improvement in the Yale Brown
bsessive Compulsive Scale (Y-BOCS) and CGI-S, but not the CGI-
, in the NAC group compared to the placebo group (Afshar et al.,
012). The study is limited due to high dropout rates. Signiﬁcant
ecrease in Y-BOCS from 33 to 9 was seen with NAC add on treat-
ent to Fluvoxamine in a case report (N = 1; LOE 4), with childhood
nset OCD (Laﬂeur et al., 2006).
Since there is only one LOE 2b study, the GOR is C for OCD. Also
n this study not all the outcome measures were positive. So the
ecommendations for use of NAC in OCD is limited at this time andw Clinical Evaluation from the Longitudinal Interval Follow-up Evaluation; SOFAS,
further larger controlled studies are needed to see the effectiveness
of NAC in treatment of OCD (Table 15).
3.1.13. Schizophrenia
A large DBPC study (N = 140; LOE 1b) reported signiﬁcantly
greater improvement in the NAC group in all qualitative and a few
quantitative measures (Berk et al., 2008a, 2011b) Another small
sized DBPC study (N = 42; LOE 2b) examining the addition of NAC
to risperidone in an 8 week trial found improvement in PANSS
negative and total scales (Farokhnia et al., 2013). Additionally, a
case report (N = 1; LOE 4) documented improvements in a 24-year-
old women with treatment resistant schizophrenia after 7 days
of 0.6 g/day of NAC as assessed by the PANSS and CGI-S (Bulut
et al., 2009). With one LOE 1b study, the GOR  for use of NAC in
schizophrenia is B. Clearly NAC is a novel treatment for schizophre-
nia but further high-quality clinical trials are needed to conﬁrm the
ﬁndings (Table 16).
3.1.14. Traumatic brain injury (TBI)
One DBPC study (N = 80; LOE 1b) showed positive response to
NAC on top of usual treatment in blast related mild TBI in active
duty service members. Use of NAC was  associated with a sig-
niﬁcant improvement in mild TBI symptoms, neuropsychological
testing results, and complete symptom resolution when compared
to placebo. Early treatment initiation within 24 h of the injury inde-
pendently showed improvement in symptoms (Hoffer et al., 2013).
Since there is one LOE 1b study, the GOR is B for NAC use in TBI. Even
though the study is positive, it is hard to make recommendation
based on just one positive study. Early treatment with NAC seems to
be a promising treatment for mild TBI and further controlled trials
showing consistent improvements on NAC are needed (Table 17).
In a related traumatic neurodegenerative model, NAC has shown
preliminary promise in a study of the prevention of noise induced
hearing loss. While the study was negative on the primary outcome,
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Table  12
Epilepsy.
Study Participants
# Group (M,  F);
age (SD)
Treatment Study
design
Outcome
measure
Effect of NAC AE Level/point
Uncontrolled studies
Hurd et al.
(1996)
Siblings with
ULD
Case 1: 33 yo M
Case 2: 35 yo F
Case 3: 38 yo M
Case 4: 39yo M
4–6 g/d NAC for
1 and 2: 30 mo
3 and 4: 26 mo
Case series Symptoms and
functioning
1: Improved
verbalization,
conversation skills,
basic daily functioning,
understanding abilities
2: Improved basic
living skills – eating,
toileting, walking
3  and 4: Improved
turning in bed,
speaking few words
One case had
diarrhea
4/1
Selwa (1999) 40 yo M with
ULD
3 g BID NAC for
10 mo
Case report Overall
symptoms
Improved tremors,
myoclonus, talking and
walking
NR 4/1
Ben-
Menachem
et al. (2000)
Progressive
myoclonic
epilepsies
Case 1: 22 yo F
Case 2: 20 yo F
Case 3: 24 yo M
Case 4: 30 yo M
Case 5: 21 yo F
NAC:
1 and 2:
4–6 g/d for
60 mo
3: 6 g/d for
3 mo
4: 4–6 g/d for
24 mo
5: 4 g/d for
6 mo
Case series Overall
symptoms
1: Improved ataxia,
GTCS, myoclonus and
functioning
2:  Improved
myoclonus, GTCS and
functioning
3:  Improved
myoclonus and general
cognition but patient
died 3 mo later due to
other medical
complications
4: Improved walking,
myoclonus, ataxia and
self-care
5: Improved
myoclonus, GTCS,
absence seizures,
ataxia and mental
function for 3 mo then
deterioration (NAC
stopped at 6 mo)
None 4/0.5
Edwards et al.
(2002)
ULD
Case 1: 38 yo F
Case 2: 30 yo F
Case 3: 48 yo F
Case 4: 35 yo M
NAC:
1: 3.6 g/d for
12 mo
2: 3.6 g/d for
24 mo
3: 3 g/d for
5 wk
4: 3 g/d for
3 mo
Case series Seizures, ataxia
and other
symptoms
1: Improved GTCS but
not myoclonus and
ataxia
2: Dramatically
improved myoclonus,
ataxia, and alertness
3: Slightly improved
myoclonus
4: Improved
myoclonus only for
initial 2 mo
1: Possible
neutropenia 2:
None
3: SN deafness
(NAC stopped
in 5 wk)
4: Nausea,
epigastric pain
4/0.5
A senso
t
o
3
a
a
t
A
c
a
t
t
A
A
tE, adverse effects; GTCS, Generalized Tonic Clonic Seizures; NR, not reported; SN, 
he rate of threshold shifts, there was signiﬁcance in a secondary
utcome and post hoc analyses (Kopke et al., 2015).
.2. Adverse effects reported in controlled clinical trials
It is important to consider the adverse effects proﬁle of
ny new treatment. It is difﬁcult to judge the signiﬁcance of
dverse effects (AEs) reported in uncontrolled trials and con-
rolled trials provide a more objective indication of signiﬁcant
Es. However, rather rare AEs may  not be statistically signiﬁ-
ant in controlled clinical trials, thus it is important to consider
ll reported possible AEs. Here we consider both AEs from con-
rolled clinical trials as well as those reported in uncontrolled
rials.For the most part, controlled trials did not report signiﬁcant
Es in the NAC treated groups as compared to the placebo group.
dverse effects involved different systems including gastroin-
estinal, neurological, psychological/behavioral, musculoskeletal,rineural; ULD, Unverricht–Lundborg Disease.
dermatological, and other systems. Details of AE speciﬁc to a par-
ticular disorder are tabulated in Table 18. The largest rate of AEs
were seen in an open-label study on cannabis in which 63% of
the participants reported mild to moderate AEs, primarily consist-
ing of abdominal discomfort, muscle pains, insomnia, headache,
nasal congestion, runny nose, nausea, weight loss, restlessness, and
dizziness (Gray et al., 2010). Very few studies reported severe AEs
leading to discontinuation of NAC including full body rash in a
TTM DBPC (Bloch et al., 2013); aggression in a child with nail bit-
ing (Ghanizadeh et al., 2013); and SN deafness in a case of ULD
(Edwards et al., 2002). In studies of ALS where subcutaneous injec-
tions were used, swelling, granuloma, and an abscess at injection
sites were reported along with hypersensitivity reactions (De Jong
et al., 1987; Küther and Struppler, 1987). Serious AE of possible
neutropenia was reported in a case series on ULD (Edwards et al.,
2002). Interestingly, in a study on schizophrenia Extrapyramidal
Symptoms Rating Scale (ESRS) were signiﬁcantly lower for the
NAC + risperidone group as compared to the placebo + risperidone
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Table 13
Impulse control disorder.
Study Participants
# Group (M,  F); age
(SD)
Treatment Study design Outcome
measure
Effect of NAC AE Level/point
Controlled studies
Nail biting
Ghanizadeh
et al. (2013)
NAC: 21 (13M, 8F);
9.3 (2.8)
PB: 21 (15M 6F);
10.8 (3.1)
0.8 g/d NAC or PB
for 8 wk
DBPC parallel Total length of
all nails
Greater nail growth
in 1st but not in
2nd month
Headache,
agitation,
isolation,
aggression
2b/0.5
Trichotillomania
Grant et al.
(2009)
NAC: 25 (1M, 24F);
32.7 (10.5)
PB: 25 (4M, 21F);
35.8 (13.6)
1.2 g/d NAC × 6 wk,
then 2.4 g/d NAC
for 6 wk  or PB
DBPC parallel MGH-HPS,
PITS, CGI
Improved
MGH-HPS, PITS and
CGI
None 1b/1
Bloch et al.
(2013)
NAC: 20 (3M, 17 F);
14.0 (2.4)
PB: 19 (2M, 17 F);
13.1 (3.1)
2.4 g/d NAC or PB
for 12 wk
DBPC parallel MGH-HPS, TSC,
NIMH-TSS, CGI
No signiﬁcant
difference between
groups
Full body rash
in 1
2b/0
Uncontrolled studies
Grooming behaviors – nail biting, skin picking and trichotillomania
Odlaug and
Grant (2007)
Case 1: 28 yo M
with nail-biting
and
trichotillomania
Case 2: 40 yo F with
trichotillomania
Case 3: 52 yo F
with skin picking
NAC:
1: 1.2 g/d for 2 wk
2: 2.4 g/d for 5 mo
3: 1.8 g/d for 4 mo
Case series Frequency of
engaging in
grooming
behaviors
Improvement in
grooming behavior
frequency
Mild ﬂatulence
in case 1
4/1
Nail  biting
Berk et al.
(2009)
BPAD and nail
biting
Case 1: 46 yo F
Case 2: 44 yo F
Case 3: 46 yo M
NAC:
1: 1 g BID for 7 mo
2: 1 g BID for 2 mo
3: Dose NR for
28 wk
Case series Nail biting
frequency
(self-report)
Improved nail
biting frequency
None 4/1
Skin  picking
Grant et al.
(2012)
24 yo F Dose NR for 1 yr Case report Skin picking
frequency
(self-report)
Improved skin
picking frequency
None 4/1
Miller and
Angulo
(2014)
Prader–Willi
syndrome and
skin-picking
35 (23F, 12M);
5–39 yo
0.450–1.2 g/d NAC
for 12 wk
Open-label Number of skin
lesions
71% complete
resolution of
skin-picking and
remainder had
signiﬁcant
improvement in
skin-picking
Abdominal
cramping,
diarrhea and
ﬂatulence
4/1
Silva-Netto
et al. (2014)
Case 1: 45 yo F with
skin picking and
trichotillomania
Case 2: 40 yo F
with skin-picking
Case 3: 31 yo F
with skin-picking
NAC:
1: 1.2–1.8 g/d;
duration NR
2: 1.2 g/d for 10 mo
3: 1.2 g/d; duration
NR
Case series Symptoms 1: Improved
trichotillomania
and skin-picking
2: Improved
skin-picking
3: Improved
skin-picking
NR 4/1
Trichotillomania
Rodrigues-
Barata et al.
(2012)
Case 1: 23 yo F
Case 2: 19 yo F
NAC:
1: 1.2 g/d for 6 mo
2: 1.2 g/d for 3 mo
Case series Regrowth of
hair
Complete regrowth
achieved
None 4/1
Taylor and
Bhagwandas
(2014)
58 yo F 1.2 g/d NAC for
32 wk
Case report Regrowth of
hair
Improved hair
growth
NR 4/1
A ouble
S ; NR, n
S
g
o
a
t
l
i
dE, adverse effects; BPAD, bipolar disorder; CGI, Clinical Global Impression; DBPC, D
cale; NIMH-TSS, National Institute of Mental Health Trichotillomania Severity Scale
cale  for Children.
roup suggesting that it might be protective against adverse effects
f other psychiatric medications when used as an adjunctive ther-
py (Farokhnia et al., 2013).
For the most part, NAC, especially oral formulation was  found
o be safe with a low incidence of AEs in most studies. The excel-
ent safety proﬁle of NAC and favorable treatment effects support
t as an excellent novel treatment for psychiatric and neurological
isorders especially in oral formulation. Blind Placebo Controlled; MGH-HPS, Massachusetts General Hospital Hair Pulling
ot reported; PITS, Psychiatric Institute Trichotillomania Scale; TSC, Trichotillomania
4. Discussion
NAC has been investigated as a novel treatment for a wide
range of psychiatric disorders and a few neurological disorders.
Studies suggest that NAC is a favorable treatment for several dis-
orders while the evidence of its effectiveness for other disorders
is less clear. The exact reason of this differential response is not
obvious. NAC works through several different metabolic pathways.
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Table  14
Neuropathy.
Study Participants
# Group (M,  F); age
(SD)
Treatment Study design Outcome
measure
Effect of NAC AE Level/point
Controlled studies
Lin et al. (2006) Participants with stage
III  colorectal cancer on
postoperative
oxaliplatin with a
ﬂuorouracil/leucovorin
regimen
NAC: 5 (4M, 1F); 58
(41–75)
PB: 9 (5M, 4F); 65
(43–78)
1.2 g NAC or PB,
90 min before
oxaliplatin
administration for
18 mo
DBPC parallel Development
of neuropathy
Positive effect in
preventing
oxaliplatin induced
neuropathy
NR 2b/1
Uncontrolled studies
Baker and
Lipson
(2010)
46 yo M with ALL and
vincristine induced
peripheral neuropathy
50 mg BID NAC,
150 mg  TID
Levocarnitine and
35 mg/d Pyridoxine
for 5 mo
Case report Motor function Motor function
returned to near
normal
NR 4/1
AE, adverse effects; DBPC, Double Blind Placebo Controlled; NR, not reported; PB, placebo.
Table 15
Obsessive compulsive disorder (OCD).
Study Participants
# Group (M,  F); age
(SD)
Treatment Study design Outcome
measure
Effect of NAC AE Level/point
Controlled studies
Afshar et al.
(2012)
Participants with OCD
on SSRI
NAC: 24 (6M, 18F);
30.62 (5.35)
PB: 24 (6, 18); 31.25
(4.70)
0.6 g/d NAC titrated
to 2.4 g/d
depending on CGI
or PB for 12 wk
DBPC parallel Y-BOCS CGI-S
CGI-I
Signiﬁcant
improvement
in Y-BOCS and
CGI-S but not
CGI-I
Nausea, vomiting,
diarrhea
2b/0.5
Uncontrolled studies
Laﬂeur et al.
(2006)
58 yo F with OCD on
Fluvoxamine 300 mg
daily
0.6 g/d NAC titrated
up to 3 g/d for 7 wk
Case report Y-BOCS Marked
decrease in
Y-BOCS
Few episode of
mild, brief right
hand tingling and
single day of dry
mouth
4/1
AE, adverse effects; CGI-I, Clinical Global Impression Improvement Scale; CGI-S, Clinical Global Impression Severity Scale; DBPC, Double Blind Placebo Controlled; PB, placebo;
SSRI,  selective serotonin reuptake inhibitor; Y-BOCS, Yale Brown Obsessive Compulsive Scale.
Table 16
Schizophrenia.
Study Participants
# Group (M,  F);
age in year (SD)
Treatment Study design Outcome
measure
Effect of NAC AE Level/point
Controlled studies
Berk et al.
(2008a)
140 (98M, 32F);
36.6 (10.9)
NAC: 69 (48M,
21F)
PB: 71 (50M, 21F)
2 g/day NAC or
PB for 4 mo
DPBC parallel PANSS, CGI,
GAF, SOFAS,
BAS, SAS, AIMS
Improvement on CGI,
PANSS but no other
outcome measures
Not signiﬁcant 1b/0.5
Berk et al.
(2011b),
Qualitative analysis
showed improved
mental state
Farokhnia et al.
(2013)
NAC: 21 (9M,
12F); 32.2 (6.1)
PB: 21 (11M,
10F); 33.4 (7.0)
2 g/d NAC or
PB + risperidone
for 8 wk
DBPC parallel PANSS, HDRS Improvement in PANSS
negative and total
scales
None 2b/1
Uncontrolled studies
Bulut et al.
(2009)
24 yo F 0.6 g/d for 67
days
Case report PANSS, CGI-S Decrease in PANSS and
CGI-S
None 4/1
AE, adverse effects; AIMS, Abnormal Involuntary Movement Scale; BAS, Barnes Akathisia Scale; CGI-S, Clinical Global Impression Severity Scale; DPBC, Double Blind Placebo
Controlled; GAF, Global Assessment of Functioning; HDRS, Hamilton Depression Rating Scale; PANSS, Positive and Negative Syndrome Scale; PB, placebo; SAS, Simpson–Angus
Scale; SOFAS, Social and Occupational Functioning Assessment Scale.
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Table 17
Traumatic brain injury (TBI).
Study Participants
# Group (M,  F); age
(SD)
Treatment Study design Outcome measure Effect of NAC AE Level/point
Controlled studies
Hoffer et al.
(2013)
Mild TBI secondary
to blast exposure
80M, 1F; 18–43 yo
NAC: 40
PB: 41
4 g loading dose
NAC then 2 g BID
for 4 days then
1.5 g BID or PB for 7
days
DBPC parallel Resolution of dizziness,
hearing loss, headache,
memory loss, sleep
disturbance and
neurocognitive dysfunction
(COWA, AN, TMT)
Signiﬁcant
improvement
in all measures
NR 1b/1
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rail  Making Test A and B.
his differential response may  be due to different metabolic path-
ays underlying the pathophysiology of various psychiatric and
eurological disorders and the differential effect of NAC on these
athways. Studies on most of the psychiatric disorders, including
utism, AD, schizophrenia, cocaine addiction, cannabis addiction,
PAD, MDD, trichotillomania, nail biting and OCD, demonstrated
ixed results. For other psychiatric disorders, speciﬁcally metham-
hetamine, nicotine, and pathological gambling addictions, the
vidence for the effectiveness of NAC was negative overall. No
ecommendations could be made for two psychiatric disorders –
nxiety and ADHD. Study on anxiety was only preliminary (i.e., case
eport) while the evidence for ADHD was based on a very speciﬁc
opulation (SLE) hence not fully representative of idiopathic ADHD.
he majority of the psychiatric disorders were assigned a GOR of
 or C. Thus, the recommendations for use of NAC in the majority
f psychiatric disorders are still limited based on the number and
he quality of studies that have been conducted and available for
eview at the time of this review. In terms of neurological disorder,
or mild TBI there was one positive DBPC study making NAC a poten-
ially promising treatment option, but it is difﬁcult to give a speciﬁc
ecommendation based on a single study. NAC showed positive
esponse in anticancer medicines induced neuropathy in a small
ontrolled trial and a case study making it a favorable treatment
ption for this indication, but since the sample size of the controlled
tudy was very small, it is hard to give any speciﬁc recommenda-
ion based on the limited current evidence. Similarly evidence of
se was mixed ranging from dramatic to partial or no improve-
ent along with AEs in progressive myoclonus epilepsy. For ALS
he evidence of the effectiveness of NAC in survival was  negative
verall. While larger controlled trials are needed to establish effec-
iveness of NAC, based on the evidence so far and excellent safety
roﬁle, NAC appears to be a favorable and novel treatment option
or several psychiatric and neurological disorders and these results
re encouraging.
The presumed mechanisms of action of NAC may  make clin-
cal sense for its use in psychiatric and neurological disorder.
AC has been demonstrated to work on multiple pathways that
ave been implicated in various psychiatric and neurological
isorders – oxidative stress, mitochondrial dysfunction, inﬂamma-
ory mediators, neurotransmission, and neural plasticity (Bavarsad
hahripour et al., 2014; Berk et al., 2013; Dean et al., 2011;
oussawi et al., 2009). Potential mechanisms of action are sum-
arized below.
.1. Potential mechanisms of action
.1.1. Oxidative stress
Oxidative stress refers to a pathological state which occurs when
he level of reactive oxygen species (ROS) is elevated to a level at
hich cellular damage can occur. This can be due to abnormally
igh levels of ROS, a deﬁcit of cellular protective mechanisms, orPBC, Double Blind Placebo Controlled; NR, not reported; PB, placebo; TMT, Timed
both (Gandhi and Abramov, 2012; Smaga et al., 2012). Oxidative
stress is involved in the pathogenesis of multiple psychiatric and
neurological disorders including BPAD (Fullerton et al., 2010; Kunz
et al., 2008), autism (James et al., 2004, 2006, 2008, 2009; Melnyk
et al., 2012; Rose et al., 2012a, 2012b), depression (Behr et al., 2012;
Smaga et al., 2012), schizophrenia (Kunz et al., 2008; Okusaga,
2014; Wu  et al., 2013), OCD (Selek et al., 2008), AD (Markesbery,
1999), ULD (Arakawa and Ito, 2007), ALS (Louwerse et al., 1995)
and drug induced neuropathy (Baker and Lipson, 2010; Lin et al.,
2006). The brain is uniquely vulnerable to ROS, due to its high oxy-
gen metabolism and limited antioxidant capabilities (Smaga et al.,
2012). Highly reactive compounds like hydroxyl radical, hydro-
gen peroxide, superoxide and peroxynitrite cause oxidative cellular
dysfunction through processes like lipid peroxidation, inactivation
of enzymes, malfunction of the mitochondrial respiratory chains,
DNA modiﬁcation and/or cell death (Maes et al., 2011; Smaga
et al., 2012). Postmortem brain specimens in several psychiatric
disorders have shown oxidative damage (Gawryluk et al., 2011).
Protective antioxidant mechanisms such as superoxide dismutase,
catalase, glutathione (GSH) reductase and glutathione peroxidase
neutralize reactive species (Maes et al., 2011; Smaga et al., 2012).
Reduction in GSH has been shown in depression (Bilici et al., 2001),
BPAD (Andreazza et al., 2009) and schizophrenia (Altuntas et al.,
2000) supporting the role of redox imbalance in psychiatric disor-
ders.
NAC provides cysteine that is rate limiting amino acid in GSH
production (Dringen and Hirrlinger, 2003). GSH carries a free thiol
group that acts as a reducing agent. GSH reduces the superoxide
radical into hydrogen peroxide which can then be neutralized to
water by catalase activity. During this processes, GSH becomes
oxidized into glutathione disulphide (GSSG). The cysteine/cysteine
cycle can also serve as a direct free radical scavenging system
(Banjac et al., 2008; Vene et al., 2011). Several preclinical stud-
ies have shown direct and indirect antioxidant effects of NAC, for
example, NAC signiﬁcantly improves antioxidant defenses in alco-
hol treated rats (Achat-Mendes et al., 2007; Flora, 1999; Fukami
et al., 2004; Seiva et al., 2009; Smaga et al., 2012; Wan  et al., 2006).
4.1.2. Mitochondrial dysfunction
Mitochondrial dysfunction occurs in several psychiatric disor-
ders (Shao et al., 2008) including schizophrenia (Robicsek et al.,
2013), BPAD (Konradi et al., 2004), autism (Rossignol and Frye,
2012), AD (Wang et al., 2014) and TBI (Lifshitz et al., 2004). The role
of mitochondrial dysfunction in the pathophysiology of psychiatric
disorders is supported by the fact that psychiatric symptoms are
common in mitochondrial disorders (Anglin et al., 2012a, 2012b,
2012c, 2012d). Mitochondria are the site for multiple redox reac-
tion in order to generate adenosine triphosphate (ATP) energy
and hence are a major source of ROS in the cell that can lead
to oxidative injury (Sullivan et al., 2007). NAC has been shown
to have direct effects on mitochondrial functioning in different
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Table 18
Reported adverse effects (AE) of N-acetylcysteine.
AE Addiction AD ALS Anxiety ADHD Autism BPAD Dep Epilepsy Impulse control disorder Neuropa-
thy
OCD Schizoph-
renia
TBI
Cannabis Cocaine MAP  Nicotine PG Nail
biting
Skin
picking
TTM
Gastrointestinal AE
Mild abdominal
pain/discomfort
x  x x x x x
Flatulence x x X
Abdominal cramps X x x X
Nausea, heart
burns, vomiting,
diarrhea
x x x x x x x x x
General GI
symptoms
x x
Neurological/psychological/behavioral AE
Headaches x x x x x
Tingling x
Vivid  dreams x
Insomnia X
Irritability/agitation x x
Other system AE
Elevated BP x
Purities/local rash x
Hypersensitivity x
Injection site
reaction
X
Allergic reaction x x
Fatigue/change in
energy
x x x
Dry
mouth/increased
thirst/sweating
x  x
Muscle/joint pain x x
General
musculoskeletal
symptoms
x
Nasal conges-
tion/runny
nose
x  x
Restlessness x
Dizziness x x
Neutropenia x
Chest  pain x
Leg edema x
Severe AE needing discontinuation
Full body rash x
Severe  aggression x
Other  severe AE x x x
SN  deafness x
AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; ADHD, attention deﬁcit hyperactivity disorder; BP, blood pressure; BPAD, bipolar disorder; Dep, depressive disorder; GI, gastrointestinal; MAP, methamphetamine;
OCD,  obsessive compulsive disorder; PG, pathological gambling; SN, sensorineural; TBI, traumatic brain injury; TTM, trichotillomania.
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isorders. As mentioned above NAC is the precursor of the most
bundant intracellular antioxidant, GSH, and also acts as a direct
ree radical scavenger and hence plays a very important role
n reducing the incidence and burden associated with oxidative
njury. NAC has shown to improve mitochondrial functioning in
nimal models of inﬂammatory bowel disease through regener-
tion of mitochondrial membrane potential and hence decreases
embrane permeability and apoptosis (Amrouche-Mekkioui and
jerdjouri, 2012). Similarly the effect of NAC on mitochondrial
embrane potential along with oxidative injury has been shown in
ung epithelial cells (Tobwala et al., 2013). NAC has shown similar
ffect on mitochondrial functioning in an animal model of myocar-
ial infarction (Basha and Priscilla, 2013) and Huntington disease
elated mitochondrial dysfunction (Sandhir et al., 2012).
.1.3. Inﬂammatory mediators
Several psychiatric disorders have been associated with a
erangement of inﬂammatory cytokines including interleukin (IL)-
, IL-2, IL-6, interferon (IFN), tumor necrosis factor  (TNF ), the
oluble IL-6 receptor (sIL-6R), and the IL-1 receptor antagonist (IL-
RA) including depression (Dowlati et al., 2010), BPAD (Tsai et al.,
014) and schizophrenia (Drexhage et al., 2010). Nuclear factor
appa-light-chain-enhancer of activated B cells (NF-B), proinﬂam-
atory cytokines, and intercellular adhesion molecule-1 (ICAM-1)
re upregulated after TBI (Chen et al., 2008). Treatment with
ytokines IL-2 and IFN  in diseases such as cancer are associated
ith high rates of depression (Capuron et al., 2000, 2001, 2004).
ytokines activate brain macrophages that lead to the release of
nﬂammatory mediators resulting in oxidative stress and neuro-
oxicity (Rajkowska and Miguel-Hidalgo, 2007).
NAC has anti-inﬂammatory properties through several cellular
rocesses. It is a GSH precursor and direct antioxidant, and hence
nhibits upstream events leading to NF-B activation (Baeuerle and
enkel, 1994) and other proinﬂammatory cytokines. This inhibi-
ion of proinﬂammatory transcription factor NF-B by NAC down
egulates expression of several proinﬂammatory genes (Yang et al.,
002). NAC directly inhibits the inﬂammatory cytokines TNF, IL-
 and IL-6, at the protein and mRNA levels, in LPS-activated
acrophage cell lines (Palacio et al., 2011) along with a direct
ffect on brain macrophages through increased GSH production,
ntioxidant properties and cysteine/glutamate exchange and hence
egulating glutamergic excitatory neuronal damage and redox
eactions (Kigerl et al., 2012).
By suppressing the activation of NF-B, NAC has shown to
educe lung inﬂammation (Blackwell et al., 1996). NAC has also
een shown to reduce IL-6 levels in dialysis patients (Nascimento
t al., 2010), TNF  and IL-1 in cardiac injury after aortic aneurysm
epair (Mahmoud and Ammar, 2011), and multiple other inﬂam-
atory cytokines in burn patient (Csontos et al., 2012). NAC is
s effective as an anti-inﬂammatory agent in animal models of
raumatic brain injury (Chen et al., 2008) and ischemia (Khan
t al., 2004), lipopolysaccharide-induced pulmonary edema (Gatti
t al., 1993), lethal endotoxemia (Victor et al., 2003) and hypoxia-
schemic brain injury in neonatal rat brains (Jatana et al., 2006).
.1.4. Glutamate neurotransmission
Abnormal glutamate signaling has been shown in multiple psy-
hiatric illnesses including schizophrenia (Kantrowitz and Javitt,
010a, 2010b), OCD (Chakrabarty et al., 2005), autism (Rubenstein
nd Merzenich, 2003) and addiction, primarily cocaine addic-
ion (Baker et al., 2003; Bauzo et al., 2012; Carlezon and Nestler,
002; Cornish and Kalivas, 2000, 2001; Pierce et al., 1996). Vesicu-
ar release of glutamate at Prefrontal Cortex-Nucleus Accumbens
PFC-NA) synapses contributes to the basal tone of glutamate.
his is negatively regulated by extrasynaptic glutamate activation
f extrasynaptic group II metabotropic autoreceptors mGluR2/3avioral Reviews 55 (2015) 294–321
(Baker et al., 2002a, 2002b; Kupchik et al., 2012). Extracellular
glutamate is regulated primarily by cystine–glutamate exchang-
ers (System Xc−) located on glial cells (Baker et al., 2002a; Bauzo
et al., 2012; Pow, 2001). These transporters exchange extracellular
cystine for intracellular glutamate (Kupchik et al., 2012; McBean,
2002). System Xc− also plays a very important role in GSH pro-
duction and hence plays an important role in regulating oxidative
stress. Glutathione is synthesized by uptake of l-cystine in the
glial cells that is released later out of the cell as GSH via the
Cys2/CysH shuttle (Dringen et al., 1999; Kranich et al., 1998; Wang
and Cynader, 2000).
Studies have shown both increased and decreased glutamate
levels in different psychiatric disorders speciﬁcally schizophrenia
(Baker et al., 2008) and addiction (Schmaal et al., 2012). Increased
glutamatergic release from a wide range of glutamatergic projec-
tions extending from the PFC to the NA is seen in animal models of
active drug seeking and reinstatement (Baker et al., 2003; Cornish
and Kalivas, 2000; Di Ciano and Everitt, 2001; Everitt and Wolf,
2002; Goldstein and Volkow, 2002; McFarland and Kalivas, 2001;
Park et al., 2002). Studies have also shown reduced basal glutamate
levels in the NA associated with substance withdrawal (Baker et al.,
2003; Hotsenpiller et al., 2001; Kupchik et al., 2012; McFarland
et al., 2003; Pierce et al., 1996). Excess of glutamate can lead to
NMDA activation leading to increased excitatory neuronal dam-
age and degeneration (Barger and Basile, 2001; Piani and Fontana,
1994; Sattler and Tymianski, 2001). Excitatory glutamate related
injuries have been shown to have a role in several neurodegen-
erative disorder including epilepsy, trauma, ALS and AD (Lipton
and Rosenberg, 1994). Studies have shown that the activation of
group I mGlus receptors can be neurotoxic by increased excita-
tory signals or neuroprotective by inhibiting the ROS generation
and intracellular GSH loss (Allen et al., 2000; Deng et al., 2004).
NAC is rapidly converted into cystine after administration and
enters cell through this cysteine transporters to activate system
Xc− (Kau et al., 2008; Kupchik et al., 2012). NAC dose-dependently
increases extracellular glutamate by restoring cystine–glutamate
exchange via system Xc− and thus bringing extracellular gluta-
mate to normal range (Baker et al., 2003; Madayag et al., 2007).
This normalization of extracellular glutamate by NAC restores tone
onto presynaptic inhibitory metabotropic glutamate autorecep-
tors in the NA and blunts the increased glutamate release (Baker
et al., 2003; Moran et al., 2005). NAC also provides the rate limit-
ing component, cysteine for GSH production and hence has role in
modulation of NMDA related injury via effect on GSH or its deriva-
tives (Gilbert et al., 1991; Leslie et al., 1992; Varga et al., 1997). Both
these actions of NAC together affect the excitatory neuronal dam-
age and glutamate homeostasis. Magnetic resonance spectroscopy
data suggests that NAC normalizes glutamate in cocaine addiction,
increases brain glutathione, and alters neural markers, including
glutamate–glycine and myoinositol (Das et al., 2013; Holmay et al.,
2012; Schmaal et al., 2012).
4.1.5. Long term neuroadaptation
Dysregulated glutamate homeostasis can lead to impaired
synaptic potentiation and plasticity and thus altered metaplastic-
ity (Moussawi et al., 2009). Metaplasticity refers to the ability to
generate synaptic plasticity (ability of synapses to strengthen or
weaken over time in response to their activity level) and can be
adaptive or maladaptive. This change in synaptic plasticity hap-
pens when a priming activity like substance administration alters
the capacity of a subsequent high or low frequency stimulation
in inducing long-term potentiation (LTP) or long term depression
(LTD)(Abraham, 2008). Several studies found that rats withdrawn
from cocaine self-administration had a marked deﬁcit in LTP and
LTD in the NA core following stimulation of PFC and NAC treatment
restored the ability to induce LTP and LTD by stimulating mGluR2/3
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nd mGluR5, respectively (Kupchik et al., 2012; Moussawi et al.,
009). Neuroplasticity is important in mental health and maladap-
ive neuroplasticity could lead to psychiatric disorders (Kays et al.,
012). This mechanism is worth further exploration in different
sychiatric disorders
.1.6. Dopamine neurotransmission
Dopamine (DA) has been linked to the pathophysiology of
chizophrenia, addiction, BPAD, depression, and ADHD (Berk et al.,
007; Heinz and Schlagenhauf, 2010; Hyman et al., 2006; Malhi and
erk, 2007; Wu et al., 2012). The reciprocal interaction between
opamine and glutamate in brain has been an area of focus in
nderstanding the pathology of psychiatric illnesses including drug
ddiction (Sesack et al., 2003) especially methamphetamine addic-
ion. Methamphetamine releases high levels of DA. DA itself has
he potential to cause oxidative injury and hence dysregulation
f DA transmission can lead to neurotoxicity (Hastings, 2009).
epeated administration of methamphetamine damages DA nerve
erminals (Cadet et al., 2003; Davidson et al., 2001; Fukami et al.,
004; Fumagalli et al., 1998) as evident by a marked reduction of
A transporter demonstrated using positron emission tomography
n the brain of methamphetamine abusers (Fukami et al., 2004;
ekine et al., 2001, 2003; Volkow et al., 2001a, 2001b, 2001c). NAC
nﬂuences glutamergic neurotransmission regulation of DA release
rom presynaptic terminals (Baker et al., 2002a, 2002b). Also NAC
s a GSH precursor acts as an important intracellular antioxidant
Schulz et al., 2000) and hence seems to have a signiﬁcant role in
egulating DA induced neurotoxicity in different psychiatric disor-
ers.
.1.7. Serotonergic neurotransmission
Serotonin (5HT) transmission has been target of multiple psy-
hopharmacological agents and derangement has been shown to
e associated with multiple psychiatric disorder including affective
isorders (Jobe et al., 1998), schizophrenia (Abi-Dargham, 2007),
utism (Cook et al., 1997), addiction (Jones and Kauer, 1999; Müller
t al., 2007) and OCD (Baumgarten and Grozdanovic, 1997). Role of
AC on serotonergic transmission has not been explored in details
s of yet. A recent study showed the effect of NAC in animal model of
sychosis by blocking hallucinogenic effect of serotonergic recep-
or 5-HT2AR agonist. This action seem to be mediated by increased
ysteine-glutamate antiporter followed by mGluR2 autoreceptors
ctivations, thus hence showing complex interaction between glu-
amatergic and serotonergic neurotransmission (Lee et al., 2014)
.2. Dosage and formulations
The daily dosage of NAC ranged from 0.6 g to 6 g/day with major-
ty of the studies using 2.0–2.4 g/day dosing. All the studies used
ral formulation of NAC with the exception of the four studies in
LS that used subcutaneous formulation. The shortest duration of
reatment reported was 2 days in cocaine addiction (LaRowe et al.,
007) and longest was 60 month in a case of progressive myoclonic
pilepsy (Ben-Menachem et al., 2000). Both of these studies showed
ositive outcomes. The majority of the studies had 8 weeks follow-
p and few had 3–6 months follow-up.
N-acetylcysteine is FDA-approved for acetaminophen poisoning
or 72-h oral and 21-h intravenous regimens. Seventy two-hour
ral regimen consists of 18 doses – loading dose of 140 mg/kg
nd maintenance dose of 70 mg/kg every 4 h to a total dose of
330 mg/kg. Total recommended intravenous dose is 300 mg/kg
OnlineTM, 2011). This dose is much higher than used in the studies
n our review. In initial studies on ALS, 50 mg/kg/day subcutaneous
ose was used (Louwerse et al., 1995). Similarly in the study on
he use of NAC in AD, 50 mg/kg/day in three divided doses were
sed (Adair et al., 2001). So if a patient is 50 kg the total dose wouldavioral Reviews 55 (2015) 294–321 313
be 2.5 g. The rationale for this dose was not clearly stated in the
studies but due to precautionary reasons the dose may  have been
decided to be a little lower than one used for acetaminophen toxi-
city. This dose was fairly well tolerated in these studies with some
gastrointestinal side effects along with hypersensitivities and local
site reaction related to subcutaneous formulation in the ALS stud-
ies (Louwerse et al., 1995). In a follow-up AD case series, a much
lower dose of 0.6 g/day of NAC was  used as an adjunct to Vita-
min  B12 and folate (McCaddon and Davies, 2005) and it showed
positive effects. It was followed by a trial in severe OCD in which,
based on earlier study dosing, 0.6 g/day was initiated and based on
the response it was  titrated to 3 g/day over 6 weeks (Laﬂeur et al.,
2006). These case reports were followed by a crossover study to
speciﬁcally assess the safety and tolerability of three doses of NAC
– 1.2 g/day, 2.4 g/day and 3.6 g/day. The study did not show any sig-
niﬁcant difference between the three doses in terms of side effects
or effect but the retention rate appeared more in favor of the higher
doses of NAC (Mardikian et al., 2007). Also one three-arm DBPC
did not show any differential response between NAC 1.2 g/day or
2.4 g/day in treatment-seeking cocaine dependent adults (LaRowe
et al., 2013). One ADHD study and few addiction studies used
higher doses of NAC in the range of 3–4.8 g with no clear signal of
higher efﬁcacy (Garcia et al., 2013; Grant et al., 2014; LaRowe et al.,
2007; Mardikian et al., 2007). Studies on ULD used a higher dose
3–6 g/day. No clear association with increased efﬁcacy with the
higher dose was  seen. In one study increasing the dose from 4 g to
6 g/day led to cold sores and possible neutropenia that was reversed
on lowering the dose to 2.4 g/day. One other patient developed
sensorineural hearing loss on 3 g/day dose of NAC (Edwards et al.,
2002). Several case reports/series have shown positive responses
with gradual titration to the range of 1.8–2.4 g/day of NAC (Marler
et al., 2014; Odlaug and Grant, 2007; Strawn and Saldana, 2012).
Hence most of the studies used the dose around 2–2.4 g/day based
on the effect and safety proﬁle. Overall the dose range between 2
and 2.4 g/day seems to be effective and well tolerated.
4.3. Potential adverse effects
For the most part, oral NAC seemed to be fairly well toler-
ated with no signiﬁcant between group differences in most of
the controlled trials. Gastrointestinal (GI) symptoms were the
most common AEs and have been reported in autism, addiction,
ALS, epilepsy, grooming disorder and OCD studies. Adverse effects
included mild abdominal pain (Ghanizadeh and Derakhshan, 2012;
Hardan et al., 2012), mild abdominal discomfort, heartburn, ﬂatu-
lence, cramps (Edwards et al., 2002; LaRowe et al., 2006; Odlaug
and Grant, 2007; Vyth et al., 1996), nausea, vomiting and diar-
rhea (Afshar et al., 2012; Hurd et al., 1996). The largest rate of AEs
was seen in an open-level studies on cannabis in which 63% of the
participants reported mild to moderate AEs, primarily abdominal
discomfort (Gray et al., 2010).
Neurological side effects were also commonly reported rang-
ing from headaches (Adair et al., 2001; Ghanizadeh et al., 2013;
Mardikian et al., 2007); to right hand tingling in a case of OCD
(Laﬂeur et al., 2006). On the contrary lower rates in Extrapyrami-
dal Symptoms Rating Scale was seen in NAC + risperidone group
as compared to the placebo + risperidone group suggesting pro-
tective effects of NAC on AEs related to concomitant psychiatric
medications when used as adjunctive therapies (Farokhnia et al.,
2013). There were few incidents of dermatological AEs including
self-limited non-dose dependent pruritus in one study (Mardikian
et al., 2007). One child developed full body rash that required dis-
continuation of the NAC treatment (Bloch et al., 2013). Elevated
blood pressure was reported in two studies (LaRowe et al., 2006;
Mardikian et al., 2007). Other miscellaneous AEs reported were
fatigue (LaRowe et al., 2006), a single day of dry mouth (Laﬂeur
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t al., 2006), muscle pains, insomnia, nasal congestion, runny nose,
estlessness, and dizziness (Gray et al., 2010), and vivid dreams and
rritability (Grant et al., 2012).
Very few studies reported severe AEs leading to discontinuation
f NAC treatment. In a TTM DBPC study one child discontinued the
AC treatment after experiencing a full body rash which dissipated
fter discontinuing NAC (Bloch et al., 2013). A child with nail biting
iscontinued treatment due to aggression (Ghanizadeh et al., 2013).
n a large DBPC study on cannabis one individual discontinued NAC
or severe AEs (Grant et al., 2012). Two rare AE were reported in
 ULD case series – neutropenia on 6 g of NAC that improved once
he dose was dropped down to 2.4 g daily and SN deafness leading
o discontinuation of NAC at 5 weeks and it was not resolved till 9
onth of follow-up (Edwards et al., 2002). It is important to con-
ider that different formulations of NAC may  have various additives
nd ﬁllers that also could cause AEs. The few and lack of consis-
ent reports of particular severe AEs suggest that NAC is generally
onsidered a well-tolerated and safe medication overall.
In animal literature serious AEs of pulmonary hypertension has
een reported (Palmer et al., 2007) and also seizures have been
eported on overdose (Bailey et al., 2004). None of the clinical stud-
es in this review reported these AEs. Serious anaphylactic reactions
ave also been reported mostly associated with intravenous admin-
stration of NAC (Mroz et al., 1997). There were more AEs in ALS
tudies that used a subcutaneous formulation including an injec-
ion site granuloma and an abscess along with hypersensitivity and
llergic reactions (De Jong et al., 1987; Küther and Struppler, 1987).
o hypersensitivity or allergic reaction was seen in oral formula-
ion. No clear association could be seen between AEs and dose or
ype of disease. Overall across studies it seems to be safe and well
olerated with a low incidence of serious AEs.
. Conclusion
The use of NAC has been studied in several psychiatric and neu-
ological disorders and seems to be a novel treatment approach.
ata is still limited in terms of quantity and quality of studies for
ost of the disorders but overall the effect trends in a positive direc-
ion for many disorders. NAC treatment appears safe, tolerable and
ffordable. It’s a medication worth exploring further. Further well
esigned, larger controlled trials are needed for different psychi-
tric and neurological disorders. In addition, studies to elucidate
hich of its many mechanisms of action are responsible for its
fﬁcacy are required.
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Appendix 1.
Fig. 1. Selection of studies for systematic review of NAC use in different psychiatric
and neurological disorders. Flow diagram depicting inclusion and exclusion of trials
for the systematic review for each disorder. (A) Selection of studies for systematic
review of NAC use in addiction. (B) Selection of studies for systematic review of NAC
use in Alzheimer’s disease. (C) Selection of studies for systematic review of NAC use
in  amyotrophic lateral sclerosis (ALS). (D) Selection of studies for systematic review
of  NAC use in anxiety. (E) Selection of studies for systematic review of NAC use in
attention deﬁcit hyperactivity disorder (ADHD). (F) Selection of studies for system-
atic review of NAC use in autism. (G) Selection of studies for systematic review of
NAC use in bipolar disorder (BPAD) and depression. (H) Selection of studies for sys-
tematic review of NAC use in epilepsy. (I) Selection of studies for systematic review
of  NAC use in impulse control disorder. (J) Selection of studies for systematic review
of  NAC use in neuropathy. (K) Selection of studies for systematic review of NAC
use  in obsessive compulsive disorder (OCD). (L) Selection of studies for systematic
review of NAC use in schizophrenia. (M)  Selection of studies for systematic review
of  NAC use in traumatic brain injury (TBI).
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Fig. 1. (Continued)
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